Society for Research on Nicotine and Tobacco (SRNT) Europe
18th Annual Conference
Munich, Germany
6–8 September 2018

Programme
The Big Debate
Pharmacologic vs Alternative Approaches in Smoking Cessation

SEPTMBER 7, 2018 AT 12:30 - 13:30
LUDWIG-MAXIMILIANS-UNIVERSITY PSYCHIATRIC CLINIC
ALZHEIMER SAAL - ROOM: A301

FACULTY

Henri-Jean Aubin, MD, PhD
Professor
University Paris-Sud
Director of the Addiction Science Research Group in the INSERM 1018 Unit
Villejuif, France

Philip Toennesen, MD
Doctor Med Science
Rigshospitalet
Copenhagen, Denmark

Serena Tonstad, MD, PhD
Professor
Loma Linda University
Loma Linda, California
Head Physician
Oslo University Hospital
Oslo, Norway

Peter Hajek, MA, PhD
Professor of Clinical Psychology
Queen Mary University of London
London, United Kingdom

Supported by an independent educational grant from Pfizer
Dear colleagues and friends

It is a great honour to welcome you to the Department of Psychiatry and Psychotherapy at the Hospital of the Ludwig Maximilian University in Munich. Our department is devoted to finding a balance between tradition and innovation, as is our home city.

We look forward to sharing a diverse, international and exciting scientific programme with you.

As always, renowned experts and new talents from all over Europe will inform you about the latest findings of current studies. On the basis of these findings we want to build a bridge between sound science and effective practice.

This year’s conference will be centred around the topic of smoking and other diseases – does smoking make people ill or does illness make people smoke?

We want to discuss the origin and treatment of tobacco dependence in other diseases. In addition to providing sound insights into the science of tobacco dependence, our conference will also offer practical implications for its prevention and treatment.

Thanks to its unique charm, Munich the “metropolis with a heart” – manages to win over every visitor within a short period of time. Just wait and see! As the conference president and a passionate tobacco researcher I am very much looking forward to sharing this exciting and unique conference with you.

Welcome to Munich and welcome to the 18th Annual Meeting of SRNT Europe!

Dr. Tobias Rüther
Conference president
Chair, Local Organising Committee
Welcome message

Dear colleagues

On behalf of the board of the Society for Research in Nicotine and Tobacco (SRNT) Europe I also would like to say „servus“ and welcome you to join the society’s 2018 conference in Munich!

SRNT-E is the first formal chapter of SRNT, and was formed in 2010 to stimulate the generation of new knowledge concerning nicotine and tobacco at any level of research, from molecular to societal. SRNT-E organises its own scientific conference in a different European country each year. As with previous SRNT-E meetings we are looking forward to a conference where scientists present their cutting edge research from the fields of pre-clinical/basic science, clinical, epidemiology/public health, and policy research. This year, we received over 260 scientific abstracts from 32 different countries – so we will have a truly international conference.

We are very happy to sponsor 4 merit-based travel awards to support participation in the conference. The awards will go to early career researchers and will include 1000 Euros as well as free registration to the conference and conference dinner.

Furthermore, we have decided to add value to the poster presentations by organising thematic poster sessions chaired by an experienced researcher, and by offering equally valued prices for the top-3 posters of the conference.

Finally, our international tracks of the conference will be accompanied by a national track in which scientists and practitioners in tobacco research and treatment from Germany can meet and share their findings.

Univ.-Prof. Dr. Daniel Kotz
President-elect SRNT-E
Chair, Scientific Programme Committee

Welcome message

Ladies and Gentlemen, dear participants

It is a pleasure to welcome you on behalf of LMU Munich to the 18th SRNT-E Annual Conference 2018, centred around the question „Smoking and Disease – does smoking make people ill or does illness make people smoke?“.

As one of Europe’s leading research-intensive universities, with a more than 500-year-long tradition, part of LMU’s mission is to conduct basic research and tackle societal and medical challenges of our time. One of the main focus areas for research within LMU’s medical faculty is to improve treatment of common diseases and to solve public health concerns.

We are honoured and proud to host this prestigious conference and we are looking forward to learning about the latest research concerning nicotine and tobacco, both from a medical perspective as well as with a view to its societal implications. The goal of SRNT-E is to bring together researchers, physicians, psychologists, politicians and other professionals working towards understanding and treating nicotine and tobacco dependence and advancing tobacco control, with the ultimate goal of eradicating the global tobacco epidemic. LMU Munich wholeheartedly supports this endeavor and your host, our Department of Psychiatry and Psychotherapy, is working towards the same end.

I wish all participants a very successful conference in these inspiring surroundings, with fruitful discussions and many occasions to network with your colleagues.

Prof. Dr. Bernd Huber
President of the Ludwig-Maximilians-Universität Munich
Welcome message

Ladies and Gentlemen

Bavaria was the first federal state in Germany to enact comprehensive legislation for the protection of non-smokers in bars, restaurants and other public buildings. The law was preceded by six years of tough negotiations in the Bavarian Parliament. Because parliament could not reach a consensus, the decision was finally made in a referendum on 4 July 2010 in which 60% of people voted in favour of the law. Afterwards, the people of Bavaria quickly and widely accepted it.

It is hard to believe that smoking in hospitals has also only been banned since that date!

As a result of the measures taken, the number of smokers in Germany has decreased by an average of about 5% in the past 10 years. The good news is that the measures seem to be particularly successful among young smokers: the number of adolescent smokers has decreased from about 30% in 2001 to about 10%. However, we must not let up in our efforts because, unfortunately, 27% of Bavarians still smoke and, despite all the endeavours, every year about 125,000 people die as a consequence of tobacco consumption.

In addition, Germany is the second worst country in Europe when it comes to measures to curb tobacco consumption. We are the only European country that still allows tobacco advertising on posters (The Tobacco Control Scale 2016 in Europe). The considerable socioeconomic differences related to smoking are also alarming: the lower the education level and household income, the higher the tobacco consumption rate. 41.6% of people without a school leaving certificate smoke compared with 20.0% of people who have attained the qualification required to enter university (‘Abitur’). Tobacco use is thus responsible for creating and increasing socioeconomic inequalities in disease and life expectancy (DEBRA 2018).

I am pleased that the 18th SRNT-E Annual Conference 2018 is taking place in Munich, hosted by the Department of Psychiatry and Psychotherapy at the Hospital of the Ludwig-Maximilians-Universität.

The main theme of this year’s conference, ‘Smoking and disease’, promises to stimulate interesting discussions and an important scientific exchange. In addition, the clinical section, where 200 colleagues will participate in smoking cessation training, will give you the treatment tools you need.

I wish you not only good discussions and valuable insights but also some moments of relaxation in Munich – also called Italy’s most northern city because of its excellent quality of life.

Kathrin Sonnenholzner

Member of the state parliament, SPD
Chairwoman of the Committee for Health and Care
Committees

SRNT-E Board

President
Linda Bauld (United Kingdom)

Past president
Ivan Berlin (France)

President-elect
Daniel Kotz (Germany)

Honorary secretary
Marcus Munafo (United Kingdom)

Secretary
Allison Ford (United Kingdom)

Treasurer
Lynne Dawkins (United Kingdom)

Communications officer
Mirte Kuipers (The Netherlands)

Representative for Europe in SRNT
Tellervo Korhonen (Finland)

Scientific Programme Committee

Chair
Daniel Kotz (Germany)

Co-Chair
Ivan Berlin (France)

Anil Batra (Germany)

Thomas Hering (Germany)

Christoph Kröger (Germany)

Olivia Maynard (United Kingdom)

Ute Mons (Germany)

Stephan Mühlig (Germany)

Stephan Mühlig (Germany)

Alexandra Pankova (Czech Republic)

Tobias Rüther (Germany)

Local Organising Committee

Chair
Tobias Rüther

Marcus Gertzen

Catherine Glocker

Karin Koelbert

Andrea Rabenstein

Evelyne Reibert

Scientific Reviewers

Paul Aveyard (United Kingdom)

Yael Bar-Zeev (Israel)

Anil Batra (Germany)

Emmanuelle Beguinot (France)

Ivan Berlin (France)

Gallus Bischof (Germany)

Melanie Böckmann (Germany)

Titus Brinker (Germany)

Leonie Brose (United Kingdom)

Jamie Brown (United Kingdom)

Susan Collins (United States)

Ivana Croghan (United States)

Amanda Farley (United Kingdom)

Filippos Filippidis (United Kingdom)

Klaas F. Franzen (Germany)

Karine Gallopin-Morvan (France)

Nouno van Schayck (The Netherlands)

Stephan Mühlig (Germany)

Gera Nagelhout (The Netherlands)

Dennis Nowak (Germany)

Axel Pankova (Czech Republic)

Jeanine Paulick (France)

Kay Uwe Petersen (Germany)

Daniela Piontek (Germany)

Oliver Pogarell (Germany)

Andrea Rabenstein (Germany)

Leah Ranney (United States)

Elena Ratschen (United Kingdom)

Juan Miguel Rey-Pino (Spain)

Laura Rosen (Israel)

Tobias Rüther (Germany)

Hannah Sallis (United Kingdom)

Christoph Schwarzbach (Germany)

Lion Shahab (United Kingdom)

Kamran Siddiqi (United Kingdom)

Carlos Sillero (United Kingdom)

Lenka Stepanova (Czech Republic)

Francisca Sureña (Spain)

Daniel Thomas (France)

Johannes Threl (United States)

Sabina Ulbricht (Germany)

Michel Underher (France)

Onno van Schayck (The Netherlands)

Jacqueline Vink (The Netherlands)

Matthias Wicki (Switzerland)

Marc Willemse (The Netherlands)

Nathalie Wirth (France)

Gorkem Yarabas (Turkey)

Justus Zeeuw (Germany)

Kamila Zvolenska (Czech Republic)
Keynote speakers

Carole Clair
Clinical
Policlinique Médicale Universitaire (PMU)
Lausanne, Switzerland

Carole Clair is a general internist, lecturer, and researcher at the department of Ambulatory Care and Community Medicine of the University of Lausanne, Switzerland. She worked in Nancy Rigotti’s team as a research fellow at the Tobacco Research and Treatment Center of the Massachusetts General Hospital and completed a Master in Science in Epidemiology at the Harvard School of Public Health.

In 2015, she obtained a 3-year Ambizione Grant from the SNSF to conduct a research project on smoking cessation in people with type 2 diabetes. Her main research interest is the interaction between smoking and metabolism. She uses mixed methods to pursue her aims of understanding the specificities of type 2 diabetic smokers to adapt clinical interventions for smoking cessation.

Keynote: „Diabetes and smoking cessation: assessing the efficacy and metabolic impact of a smoking cessation intervention“
Friday, 7 September 2018 | 13:30 – 14:00 | Hörsaal (Lecture hall)

Ute Mons
Epidemiology / public health
German Cancer Research Center (DKFZ)
Heidelberg, Germany

Ute Mons heads the Cancer Prevention Unit at the German Cancer Research Center (DKFZ) based in Heidelberg, Germany. She holds an M.A. in Sociology and Economics, and a PhD in Epidemiology from the University of Heidelberg. She has co-authored more than 80 publications, mostly in her main research areas tobacco control, cancer prevention, and chronic disease epidemiology. Ute Mons participates in several committees in Germany to promote public health and tobacco control.

Keynote: „The role of tobacco control in the prevention of non-communicable diseases“
Thursday, 6 September 2018 | 13:30 – 14:00 | Hörsaal (Lecture hall)

Marcus Munafò
Pre-clinical/basic science
UK Centre for Tobacco and Alcohol Studies
University of Bristol, UK

Marcus Munafò is Professor of Biological Psychology at the University of Bristol, UK, and Programme Lead within the MRC Integrative Epidemiology Unit.

He joined Bristol in 2005 after completing his postdoctoral training at the University of Oxford and University of Pennsylvania.

Keynote: „Triangulation: How basic and clinical science complement each other“
Friday, 7 September 2018 | 09:00 – 09:30 | Hörsaal (Lecture hall)

Marc Willemsen
Policy
Netherlands Expertise Center for Tobacco Control (NET)
Utrecht, The Netherlands

Marc Willemsen is a national and international expert on tobacco control and tobacco policy. He published more than 150 scientific contributions on various aspects of tobacco control in national and international journals and books.

He is an endowed professor in tobacco control research at Maastricht University, the Netherlands, and is also employed as Scientific Director Tobacco Control at the Netherlands Expert Center on Tobacco Control (NET) at the Dutch Trimbos Institute.

He is lead investigator of the International Tobacco Control (ITC) Netherlands Study and is also involved in various past and present European research projects (e.g., ESCHER, SILNE, SILNE-R, EUREST-PLUS).

He chairs the Netherlands Network for Tobacco Control Researchers (NNvT).

Keynote: „The enormous time lag between recognising the tobacco problem and effective national tobacco control policies: searching for explanations“
Saturday, 8 September 2018 | 09:00 – 09:30 | Hörsaal (Lecture hall)
General information

Conference president and Chair of the Local Organizing Committee
Dr. Tobias Rüther
Clinic for Psychiatry and Psychotherapy / Tobacco Dependence Outpatient Clinic
Medical Center of the University of Munich, Munich, Germany

President-elect SRNT-E and Chair of the Scientific Programme Committee
Univ.-Prof. Dr. Daniel Kotz
Institute of General Practice, Addiction Research and Clinical Epidemiology Unit,
Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
Maastricht University | University College London | University of Edinburgh

Conference venue
Medical Center of the University of Munich
Clinic for Psychiatry and Psychotherapy
Nußbaumstraße 7
80336 Munich
Germany

Conference office
event lab. GmbH
Richard-Lehmann-Straße 12
04275 Leipzig
Germany
+49 (0) 34 1 24 05 96 50
+49 (0) 34 1 24 05 96 51
info@eventlab.org

Conference office on site | Registration desk
The conference office and luggage room are situated on the ground floor (room A 024) and will be open as follows:
Thursday, 6 September 2018 08:00 – 18:00
Friday, 7 September 2018 08:30 – 17:00
Saturday, 8 September 2018 08:30 – 13:30
You can contact the conference office on site, either by sending a message to Ms. Stefanie Bethmann at sbethmann@eventlab.org or calling her at +49 (0) 34 1 24 05 96 56.

Conference language
The official language of the conference is English and no simultaneous translation is foreseen during the scientific sessions.

Name badges
Each participant will receive an individual, non-transferable name badge upon check-in at the registration desk. The badge will be the official conference pass and should be worn at all times in order to gain entry into the lecture halls.

Certificate of attendance | CME credit points
Pre-registered participants will receive a certificate of attendance including the CME credit points granted by the Bavarian State Chambers. You can submit this certificate to your competent authority in your country of origin. The recognition then depends on the local regulations.

CME credit points are being requested at the Bavarian State Chamber of Physicians (Bayerische Landesärztekammer) and the Bavarian State Chamber of Psychological Psychotherapists and Child and Adolescent Psychotherapists (Bayerische Landeskammer der Psychologischen Psychotherapeuten und der Kinder- und Jugendlichen-psychotherapeuten).

Technical support
There is NO speakers’ preview room, and presentations will NOT be delivered to the lecture halls. Please come to the lecture hall, in which you are speaking, in good time before your session starts.

All presentations shall be based on PowerPoint 2016. Adobe Reader, and VLC Media Player are available as well, whereas Java and Firefox are NOT available. The projectors project in 4:3 format.

Please bring your presentation in the adequate version on flash drive (USB drive). Please note that you will NOT be able to use your own laptop computer.

WIFI
Bavaria will be the first federal state with its own WiFi network. By the year 2020, up to 20,000 hotspots will be made available free of charge in the BayernWLAN.

Enjoy complimentary high-speed-connection using the SSID @BayernWLAN during the conference, a service of the federal state of Bavaria.

Poster exhibition
Posters are displayed on the ground floor in the gym, the foyer of the gym and in the glass hall. The poster boards are marked with numbers referring to those in the programme. Materials for putting up the posters are provided.

The poster exhibition is open all-day during the conference days. There will be six poster sessions, at which each presenter must be available for discussion. Please refer to the scientific programme for further details.

Presenters must remove their posters until Saturday, 8 September 2018, 11:30. The organiser will not be responsible for any loss or damage occurred to the posters left on the boards beyond this time. Moreover, the staff will remove posters that have not been removed until then.

General information

Conference president and Chair of the Local Organizing Committee
Dr. Tobias Rüther
Clinic for Psychiatry and Psychotherapy / Tobacco Dependence Outpatient Clinic
Medical Center of the University of Munich, Munich, Germany

President-elect SRNT-E and Chair of the Scientific Programme Committee
Univ.-Prof. Dr. Daniel Kotz
Institute of General Practice, Addiction Research and Clinical Epidemiology Unit,
Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
Maastricht University | University College London | University of Edinburgh

Conference venue
Medical Center of the University of Munich
Clinic for Psychiatry and Psychotherapy
Nußbaumstraße 7
80336 Munich
Germany

Conference office
event lab. GmbH
Richard-Lehmann-Straße 12
04275 Leipzig
Germany
+49 (0) 34 1 24 05 96 50
+49 (0) 34 1 24 05 96 51
info@eventlab.org

Conference office on site | Registration desk
The conference office and luggage room are situated on the ground floor (room A 024) and will be open as follows:
Thursday, 6 September 2018 08:00 – 18:00
Friday, 7 September 2018 08:30 – 17:00
Saturday, 8 September 2018 08:30 – 13:30
You can contact the conference office on site, either by sending a message to Ms. Stefanie Bethmann at sbethmann@eventlab.org or calling her at +49 (0) 34 1 24 05 96 56.

Conference language
The official language of the conference is English and no simultaneous translation is foreseen during the scientific sessions.

Name badges
Each participant will receive an individual, non-transferable name badge upon check-in at the registration desk. The badge will be the official conference pass and should be worn at all times in order to gain entry into the lecture halls.

Certificate of attendance | CME credit points
Pre-registered participants will receive a certificate of attendance including the CME credit points granted by the Bavarian State Chambers. You can submit this certificate to your competent authority in your country of origin. The recognition then depends on the local regulations.

CME credit points are being requested at the Bavarian State Chamber of Physicians (Bayerische Landesärztekammer) and the Bavarian State Chamber of Psychological Psychotherapists and Child and Adolescent Psychotherapists (Bayerische Landeskammer der Psychologischen Psychotherapeuten und der Kinder- und Jugendlichen-psychotherapeuten).

Technical support
There is NO speakers’ preview room, and presentations will NOT be delivered to the lecture halls. Please come to the lecture hall, in which you are speaking, in good time before your session starts.

All presentations shall be based on PowerPoint 2016. Adobe Reader, and VLC Media Player are available as well, whereas Java and Firefox are NOT available. The projectors project in 4:3 format.

Please bring your presentation in the adequate version on flash drive (USB drive). Please note that you will NOT be able to use your own laptop computer.

WIFI
Bavaria will be the first federal state with its own WiFi network. By the year 2020, up to 20,000 hotspots will be made available free of charge in the BayernWLAN.

Enjoy complimentary high-speed-connection using the SSID @BayernWLAN during the conference, a service of the federal state of Bavaria.

Poster exhibition
Posters are displayed on the ground floor in the gym, the foyer of the gym and in the glass hall. The poster boards are marked with numbers referring to those in the programme. Materials for putting up the posters are provided.

The poster exhibition is open all-day during the conference days. There will be six poster sessions, at which each presenter must be available for discussion. Please refer to the scientific programme for further details.

Presenters must remove their posters until Saturday, 8 September 2018, 11:30. The organiser will not be responsible for any loss or damage occurred to the posters left on the boards beyond this time. Moreover, the staff will remove posters that have not been removed until then.
Abstracts
Abstracts will be available for download on the conference homepage. Please contact the conference office until 10 September 2018 at the latest in case you do not agree to the publication of your abstract.

Accompanying exhibition | Catering
The accompanying exhibition is located on the first floor and is open all-day during the conference. Please refer to page 60 of this programme booklet for further details on the exhibitors.

Food and beverages will be served on the first floor as well. Please see the timetables on pages 20 – 22 for details on the coffee and lunch breaks.

Social events
We look forward to welcoming you to our two social events. Please refer to page 58 of this programme booklet for further details.

Parking
Please note that private parking near the venue is highly limited due to the medical campus. Therefore, please use the following car parks nearby:
ALPINA Sonnenhof Parkgarage, Landwehrstraße 10, 80336 Munich
CarPark Cristal, Schwantaler Straße 36, 80336 Munich

Getting there
From the Central Station (Hauptbahnhof): Walking time of approx. 10 min (exit Goethestraße)
From Sendlinger Tor: U-Bahn-Lines U1, U2, U3, U6, U7: Walking time of approx. 5 min (exit Nußbaumstraße)
From Goetheplatz: U-Bahn-Lines U3, U6: Walking time of approx. 5 min (exit Goetheplatz)
For details on public transportation please refer to the metro plan on page 18

Tourist information
Marienplatz 8
80331 Munich
Germany
+49 (0) 89 23 39 65 00
www.muenchen.de/int/en.html

Opening hours:
Mon – Fri: 09:30 – 19:30
Sat: 09:00 – 16:00
Sun: 10:00 – 14:00

Emergency calls
Police: 110 (only in case of emergency)
Fire and health care: 112
Police headquarters
Ettstraße 2
80333 Munich
Germany
+49 (0) 89 29 10 0
## Timetable | Thursday, 6 September 2018

| 09:00 – 09:30 | Opening ceremony |
| 09:30 – 10:45 | Oral session C1, Oral session P1, Oral session E1 |
| 10:45 – 11:15 | Coffee break |
| 11:15 – 12:30 | Symposium P1, Symposium C1, Symposium E1 |
| 12:30 – 13:30 | Lunch break |
| 13:30 – 14:00 | Keynote E (Ute Mons) |
| 14:00 – 15:00 | Poster Session 1 + 2 + 3 (Gym, Foyer gym and Glass hall) |
| 15:00 – 15:30 | Coffee break |
| 15:30 – 16:45 | Oral session E2, Oral session B1, Oral session P2 |
| 16:45 – 17:45 | SRNT-E Members Meeting |
| 18:30 – 21:00 | Welcome reception, Bavarian State Parliament – Maximilianeum |

## Timetable | Friday, 7 September 2018

| 09:00 – 09:30 | Keynote B (Marcus Munafò) |
| 09:30 – 10:45 | Oral session E3, Oral session C2, Oral session P3 |
| 10:45 – 11:15 | Coffee break |
| 11:15 – 12:30 | Symposium P2, Symposium E2, Symposium C2 |
| 12:30 – 13:30 | Lunch break, Lunch symposium Medscape: The Big Debate (See page 2) |
| 13:30 – 14:00 | Keynote C (Carole Clair) |
| 14:00 – 15:00 | Poster Session 4 + 5 + 6 (Gym, Foyer gym and Glass hall) |
| 14:00 – 15:00 | Coffee break |
| 15:00 – 15:30 | Workshop (Suzanne Gage) |
| 15:30 – 16:45 | Workshop (Robert West / Marcus Munafò), Workshop (Philippe Faure / Mohammed Shoaib) |
| 16:45 – 17:45 | Dealing with media: old and new, Improving quality and replicability of research, Preclinical approaches to understanding nicotine addiction and developing novel smoking cessation treatments |
| 19:00 – 23:00 | Conference gala dinner, Restaurant BAVARIE – BMW Welt |
### Timetable | Saturday, 8 September 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session/Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 09:30</td>
<td>Hörsaal (Library)</td>
<td>Keynote P (Marc Willemsen)</td>
</tr>
<tr>
<td>09:30 – 10:45</td>
<td>Hörsaal (Lecture hall)</td>
<td>Oral session E4: Socioeconomic inequalities in smoking and quitting</td>
</tr>
<tr>
<td>10:45 – 11:15</td>
<td>Hörsaal (Meeting room)</td>
<td>Coffee break</td>
</tr>
<tr>
<td>12:30 – 13:30</td>
<td>Hörsaal (Lecture hall)</td>
<td>Closing session &amp; Farewell lunch</td>
</tr>
</tbody>
</table>

### Scientific programme | Thursday, 6 September 2018

**Opening ceremony**  
Hörsaal (Lecture hall)

- **Welcome and introduction**  
  Dr. Tobias Rüther  
  Conference president and Chair of the Local Organizing Committee
- **Presentation of the travel awards by Daniel Kotz**  
  Dr. Tobias Rüther  
  Conference president and Chair of the Local Organizing Committee

**Oral session C1**  
Hörsaal (Lecture hall)

**Smoking cessation and disease**  
Chairs: T. Rüther / M. Coja

- **Smoking and risk of neurodegenerative disease**  
  R. Perneczky / Munich, Germany

- **Using telephone follow-up to re-engage smokers in the Ottawa Model for Smoking Cessation**  
  M. Coja / Ottawa, Canada; A. Leblanc; R. Assi; M.-L. Do Couto; K. Grattan; K.-A. Mullen; R.D. Reid; L. Scholtz; A. Pipe

- **Insufficient smoking cessation in patients with diabetes after acute coronary syndrome, need for improved secondary prevention**  
  L. Clément / Lausanne, Switzerland; D. Nanchen; O. Muller; B. Gencer; R. Klingenberg; L. Räber; C.M. Matter; T.F. Lüscher; S. Windecker; F. Mach; N. Rodondi; C. Clair

- **Nicotine replacement therapy "gift cards" as incentives to help smokers quit: A pilot study**  
  K.-A. Mullen / Ottawa, Canada; S. Noble; E. Langevin; N. Martin; R.D. Reid

- **Results of a model project for fully financed tobacco cessation for patients with chronic obstructive pulmonary disease (COPD) (ATEMM-Study)**  
  S. Mühlig / Chemnitz, Germany; F. Loth; J. Bickhardt; T. Heindl
### Scientific programme | Thursday, 6 September 2018

#### Oral session P1

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 – 10:45</td>
<td>Oral session P1</td>
<td>A 201 (Library)</td>
</tr>
</tbody>
</table>

**Smoke-free places**

Chairs: M. Mlinarić / A. Brown

- Explaining mechanisms that influence the implementation of smoke-free environments at the local level: A realist review
  - M. Mlinarić / Halle (Saale), Germany: L. Hoffmann; A. Kunst; M. Schreuders; M. Willemsen; I. Moor; M. Richter
- Enhancing smoke-free environments at the local level: An empirically grounded type construction in 7 European cities
  - L. Hoffmann / Halle (Saale), Germany: M. Mlinarić; L. Buchenauer; A. Kunst; M. Richter

- Where do teens smoke? Smoking locations of adolescents in seven European countries with different levels of smoke-free legislation
  - N. Lagerweij / Amsterdam, Netherlands: M. Kuipers; A. Kunst

- Scottish prison staff views on the potential place of e-cigarettes in smoke-free prison environments
  - A. Brown / Stirling, United Kingdom: H. Sweeting; E. Demou; G. Logan; K. Hunt

- Rights, roles and relationships: Adolescent experiences of Smoke-Free School Policies in Europe
  - R. Hewer / Edinburgh, United Kingdom: S. Hill; A. Amos

#### Oral session E1

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 – 10:45</td>
<td>Oral session E1</td>
<td>A 301 (Alzheimer hall)</td>
</tr>
</tbody>
</table>

**E-cigarettes and heat-not-burn products**

Chairs: D. Kotz / A. Amos

- Heat not burn tobacco products: a systematic literature review
  - E. Simonavicius / London, United Kingdom: A. McNeill; L. Shahab; L. Brose
- Heat-not-burn products: representative data on consumer behaviour and associated factors in the German population (the DEBRA study)
  - D. Kotz / Düsseldorf, Germany: S. Kastaun

- E-cigarettes and social norms among Scottish young people – a qualitative analysis
  - A. Amos / Edinburgh, United Kingdom: A. MacGregor; H. Delaney

- Adolescent electronic cigarette use in seven European countries: A cross-national comparison
  - J.M. Kinnunen / University of Tampere, Finland: S. Li; E. Breslin; S. Keogan; L. Clancy; A. Rimpelä; P. Lindfors; B. Federico; M. Richter; J. Perelman; A. Kunst; V. Lorant

- Assessing the impact of behavioural factors on the relationship between electronic cigarette experience and subsequent cigarette experimentation: A Scottish schools cohort study
  - M. Wilson / Stirling, United Kingdom: C. Best; F. Haseen; G. Ozakinci; D. Currie

### Scientific programme | Thursday, 6 September 2018

#### Coffee break

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 – 11:15</td>
<td>Coffee break</td>
<td></td>
</tr>
</tbody>
</table>

#### Symposium P1

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15 – 12:30</td>
<td>Symposium P1</td>
<td>Hörsaal (Lecture hall)</td>
</tr>
</tbody>
</table>

- Evidence review of e-cigarettes and heated tobacco products 2018
  - Chair: A. McNeill
  - Discussant: A. Villanti

- Prevalence of e-cigarette use and harm perceptions in Great Britain
  - L. Brose / London, United Kingdom

- The effect of e-cigarette use on smoking cessation and reduction
  - D. Robson / London, United Kingdom

- Poisonings, fires and explosions
  - R. Calder / London, United Kingdom

- Health risks of e-cigarette use
  - L. Shahab / London, United Kingdom

- Discussion
  - A. Villanti / Burlington, United States

#### Symposium C1

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15 – 12:30</td>
<td>Symposium C1</td>
<td>A 201 (Library)</td>
</tr>
</tbody>
</table>

- Aspects of smoking and cessation in pregnancy and postpartum
  - Chairs: I. Berlin / C. Oncken

- Barriers and Enablers to prescribing Nicotine Replacement Therapy during pregnancy
  - Y. Bar-Zeev / Newcastle, Australia: B. Bonevski; M. Gruppetta; G. Gould

- Preventing return to smoking postpartum (pres study) – development of an evidence based complex intervention for maintaining positive behaviour change
  - C. Notley / Norwich, United Kingdom: T. Brown; R. Holland; M. Ussher; L. Bauld; S. Orton; F. Naughton; W. Hardeman; V. Maskrey

- Exposure to nicotine and toxicants among pregnant women who use e-cigarettes or exclusively smoke tobacco cigarettes
  - C. Oncken / Farmington, CT, United States: N. Atuegwu; E. Mead; M. Perez; M.L. Goniewicz; E. Mortensen

- Characteristics of smoking behaviour among pregnant smokers motivated to quit
  - I. Berlin / Paris, France

#### Symposium E1

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15 – 12:30</td>
<td>Symposium E1</td>
<td>A 301 (Alzheimer hall)</td>
</tr>
</tbody>
</table>

- Smoking cessation and prevention - the German experience
  - Chairs: M. Goecke / C. Kröger

- The smokefree campaign of the Federal Center for Health Education (BZgA)
  - K. Duhme / Cologne, Germany: M. Goecke; B. Orth
**Symposium E1 continued**

**Impact of the EU Tobacco Products Directive on call volume, counselling protocol and follow-up results of the German Quitline**
P. Lindinger / Frankfurt, Germany; M. Goecke; K. Duhme

**Be Smart – Don’t Start: Long-term effects of a school-based prevention programme**
R. Hanewinkel / Kiel, Germany; B. Isensee; M. Morgenstern

**Participants and Effects of the Smokefree Program**
C. Kröger / Munich, Germany

**12:30 – 13:30 Lunch break**

**13:30 – 14:00 Keynote lecture E (Ute Mons)**
Hörsaal (Lecture hall)

The role of tobacco control in the prevention of non-communicable diseases
Chair: T. Rüther

**14:00 – 15:00 Poster session 1 + 2 + 3**
Gym / Foyer gym / Glass hall

For more information see page 40

**15:00 – 15:30 Coffee break**

**15:30 – 16:45 Oral session E2**
Hörsaal (Lecture hall)

E-health interventions for smoking cessation
Chairs: C. Meyer / J. Thrul

**E. A Randomized Trial for a Mobile-Phone Text Messaging Programme for Tobacco Risk Communication among Young Adults in Community College**
A. Prokhorov / Houston, United States; G. Khalil; K. Calabro; T. Machado; S. Russell; G. Botello; D. Vidrine; C. Perry

**B. Mental Health Status Moderates the Success of a Mobile-Phone Text Messaging Program for Tobacco Risk Communication among Young Adults in Community College**
G. Khalil / Houston, United States; K. Calabro; T. Machado; S. Russell; G. Botello; D. Vidrine; C. Perry; A. Prokhorov

**C. Who profits from a motivational intervention targeting smoking reduction? Predictors and Moderators of Abstinence among Smokers not Ready to Quit**
C. Meyer / Greifswald, Germany; S. Ulbricht; S. Haug; A. Broda; G. Bischof; H.-J. Rumpf; U. John

**D. Using smartphone data to predict high risk episodes of smoking among young adults**
J. Thrul / Baltimore, MD, United States; L. Holmes; P. Ling

---

**Scientific programme | Thursday, 6 September 2018**

**Key:** B = basic/pre-clinical science; C = clinical; E = epidemiology/public health; P = policy

---

**15:30 – 16:45 Oral session B1**
A 201 (Library)

**Genetic and neuropsychological aspects of tobacco and e-cigarette use**
Chairs: A.-L. Wang / M.N. Smolka

**An fMRI study on the impact of advertising for flavored e-cigarettes on susceptible young adults**
K. Garrison / New Haven, United States; S. O’Malley; R. Gueorguieva; S. Krishnan-Sarin

**A novel genetic instrument for lifetime smoking indicates that smoking is a causal risk factor for depression and schizophrenia**
R. Wootten / Bristol, United Kingdom; M. Munafó

**Temporal discounting and smoking cessation: Be consistent when quitting**
M. Smolka / Dresden, Germany; N.B. Kroemer; S. Pooeh; F. Böhme; C. Grosskopf

**Associations of polygenic risk scores for smoking and alcohol use with multiple detailed measures of addiction-related behaviors in families selected for nicotine dependence**
J. Kaprio / Helsinki, Finland, Finland; T. Palviainen; M. Liu; M.L. Pergadia; P.A.F. Madden; T. Korthonen

**Emotional Content Modulates Brain fMRI and Cognitive Effects of Repetitive Exposure to Graphic Warning Labels in Adolescents**
A.-L. Wang / New York, United States; Z. Shi; V. Fairchild; C. Aaronwitz; D. Langleben

**15:30 – 16:45 Oral session P2**
A 301 (Alzheimer hall)

**Plain packaging**
Chairs: M. Kuipers / E. Sebrie

**Availability and pricing of tobacco products during, and after, the introduction of standardised packaging: Findings from independent and convenience (small) retailers in the United Kingdom**
C. Moodie / Stirling, United Kingdom; M. Stead; K. Angus; N. Critchlow; D. Eadie; A.M. MacKintosh

**Adolescents’ perceptions of tobacco accessibility and smoking acceptability in response to the tobacco point-of-sale display ban in Scotland: Results from the DISPLAY study**
M. Kuipers / Amsterdam, Netherlands; C. Best; M. Wilson; J. Pearce; M. Cherrie; G. Ozakinci; F. Haseen; D. Currie; S. Haw

**The early impacts of standardised packaging in the United Kingdom**
C. Moodie / Stirling, United Kingdom; C. Best; S. Hitchman; A. McNell

---

Page 26

---

Page 27
### Scientific programme | Thursday, 6 September 2018

#### Oral session P2 continued

Monitoring compliance with the ban on tobacco advertising, promotion and product display at the point of sale in Dakar, Senegal (February, 2018)

*E. Sebrie / Washington, United States; M. Sagna; K. Walter; F. Diouf; O. Ba; B. Camara; M. Muggli; M. Carmona*

Smoking-related perceptions before and after the implementation of plain tobacco packaging in France: DePICT a representative study

*F. El-Khoury / Paris, France; M. Melchior*

16:45 – 17:45 **SRNT-E Members meeting**  
A 201 (Library)  
Members only

18:30 – 21:00 **Welcome reception**

**Please have your ID card with you for admission.**  
For more information see page 58

The whole conference at your fingertips

Download the official SRNT-E 2018 conference APP now!

**Share your experience using** #srnte2018munich

### Scientific programme | Friday, 7 September 2018

| 09:00 – 09:30 | **Keynote lecture B**  
(Marcus Munafò) |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hörsaal (Lecture hall)</td>
<td></td>
</tr>
<tr>
<td><strong>Triangulation: How basic and clinical science complement each other</strong></td>
<td></td>
</tr>
<tr>
<td>Chair: L. Bauld</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>09:30 – 10:45</th>
<th><strong>Oral session E3</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hörsaal (Lecture hall)</td>
<td></td>
</tr>
<tr>
<td><strong>Smoking cessation in healthcare settings</strong></td>
<td></td>
</tr>
<tr>
<td>Chairs: L. Brose / M.-P. Sylvestre</td>
<td></td>
</tr>
</tbody>
</table>
| Smokers awareness, use and perceptions of effective smoking cessation support  
L. Brose / London, United Kingdom; C. Moodie; L. Bauld; E. Power |
| Rates of delivery of brief advice to stop smoking by German clinicians and associated factors: results from the German Study on Tobacco Use (DEBRA)  
S. Kastaun / Düsseldorf, Germany; D. Kotz |
| **Systematic Review of Interventions to Improve Health Providers’ Provision of Smoking Cessation Care in Pregnancy** |
| Y. Bar-Zeev / Newcastle, Australia; B. Bonevski; L.L. Lim; L. Twyman; E. Skelton; M. Gruppetta; K. Palazzi; C. Oldmeadow; G. Gould |
| The association between nicotine dependence and readiness to quit smoking and smoking-related and mental health illness among primary care patients in Crete  
C. Vardavas / Heraklion, Greece; C. Girvalaki; S. Papadakis; A. Pipe; E. Petridou; C. Lionis |
| **A prognostic tool to identify adolescents at risk of cigarette smoking initiation** |
| M.-P. Sylvestre / Montreal, Canada; N. Hanusaik; D. Berger; E. Dugas; L. Pbert; J. Winickoff; J. O’Loughlin |

<table>
<thead>
<tr>
<th>09:30 – 10:45</th>
<th><strong>Oral session C2</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>A 201 (Library)</td>
<td></td>
</tr>
<tr>
<td><strong>Factors associated with tobacco and e-cigarette use</strong></td>
<td></td>
</tr>
<tr>
<td>Chair: K. Cropsey</td>
<td></td>
</tr>
</tbody>
</table>
| Nicotine absorption from e-cigarettes over 12 months  
K. Soar / London, United Kingdom; C. Kimber; H. McRobbie; L. Dawkins |
| Changes in puffing topography in e-cigarette naïve smokers in the initial two weeks of a cessation attempt  
C. Kimber / London, United Kingdom; K. Soar; O. Corcoran; L. Dawkins |
| Anhedonia, nicotine dependence and smoking cessation outcome  
C. Martinez-Vispo / Santiago de Compostela, Spain; A. López-Durán; C. Senra; R. Rodríguez-Cano; E. Fernández del Río; E. Becoña |
**Oral session C2 continued**

You can do it if you really want – General and specific abstinence self-efficacy as relapse predictors in a structured group intervention for smoking cessation

S. Kuitunen-Paul / Dresden, Germany; C. Scheffel; M. Jakob; L.Y. Kuipers; N.B. Kroemer; P.T. Kuitunen; F. Böhme; M.N. Smolka; G. Bühringer

Self-efficacy rather than motivation was associated with early quit success

K. Cropsey / Birmingham, United States; M. Sisson; S. Schiavon

**Oral session P3**

Aspects of international policy and regulation

Chairs: C. Moodie / C. Backinger

Plain packaging: Legislative differences in Australia, France, the United Kingdom, New Zealand and Norway, and options for strengthening regulations

C. Moodie / Stirling, United Kingdom; J. Hoek; J. Scheffels; K. Gallet-Morvan; K. Lindorff

Realist exploration of adolescents access to cigarettes in seven European countries: a qualitative study

P. Nuyts / Amsterdam, Netherlands; R. Hewer; M. Kuipers; A. Kunst; S. Hill; A. Amos

U.S. Food and Drug Administration’s Comprehensive Tobacco and Nicotine Regulatory Plan

C. Backinger / Silver Spring, United States: D. van Bemmel; A. Bahde

Factors Influencing Farmers Turning into Tobacco Cultivation in the Khulna Division of Bangladesh: An Empirical Study

K.M. Hasan / Tun Mun, Hong Kong


V.H.T. So / Stirling, United Kingdom; S. Haw; C. Best; D. Currie

**Coffee break**

10:45 – 11:15

**Symposium P2**

Monitoring tobacco control in Europe

Chairs: C. Vardavas / U. Mons

Socio-demographics, tobacco control views and cessation among menthol, flavoured, and unflavoured tobacco users in Europe – Findings from the 2016 ITC/EUREST-PLUS (6E, NL, EN) Surveys

M. Zatoński / London, United Kingdom

Cessation assistance reported by smokers in eight European countries – Findings from the 2016 ITC/EUREST-PLUS (6E, NL, EN) Surveys

K. Hummel / Maastricht, Netherlands

**Symposium E2**

Reducing smoking in pregnancy and the post-partum

Chair: M. Passey

Discussant: L. Bauld

Overview and introduction

M. Passey / Lismore, Australia

Towards improving smoking cessation support in pregnancy – constructs associated with provision of cessation support to pregnant women

M. Passey / Lismore, Australia; J. Longman; C. Adams; J. Johnston; J. Simms; M. Rolfe

Developing the evidence base for supporting smoking relapse prevention postpartum alongside other cancer preventative behaviours

C. Notley / Norwich, United Kingdom; A. Kassianos; A. Kurti; F. Mitchell; D. Nostikasari; J. Payton; C. Spears; E. Ward

Smoking cessation in pregnancy incentives trial (crpi ii): from evidence to practice – the challenges

L. Sinclair / Stirling, United Kingdom; G. Lucas; L. Bauld; D. Tappin

Discussion

L. Bauld / Stirling, United Kingdom

**Symposium C2**

Formative treatment research in high-risk populations

Chair: A. Mathew

Discussant: A. McNeill

Improving Treatment Engagement in Smokers with COPD: A Qualitative Study of Patient Perspectives

A. Mathew / Chicago, United States; S. Yount; P. Subash; M. Guzman; R. Kalhan; B. Hitsman

Cervical Cancer Survivors’ Love-Hate Relationship with Smoking: A Mixed Methods Study of Smoking Persistence versus Cessation

J. Burris / Lexington, United States; G. Pulé; D. Montgomery; A. Brown

**Key:** B = basic/pre-clinical science; C = clinical; E = epidemiology/public health; P = policy
32 33

\[102x35\]Society for Research on Nicotine and Tobacco (SRNT) Europe  
18th Annual Conference in Munich, Germany, 6–8 September 2018

\[28x28\]

15:30 – 16:45  Workshop  A 201 (Library)
Improving quality and replicability of research
Speakers: Robert West; Marcus Munafò

There is a huge amount of waste in research because research methods and reporting do not permit reliable conclusions to be drawn. This workshop will cover a set of topics aimed at improving this situation: 1) ‘open science’ including pre-registration of studies and analysis plans, 2) use of registered reports, 3) use of ontologies when describing models and study methods, and 4) use of Bayesian methods to improve efficiency of data collection, and interpretation and synthesis of study findings. Topics will be introduced by one of the facilitators (10 mins each) topic with handouts. Then participants will be invited to discuss the topic with a focus on whether and how they can see proposals becoming part of their research practice, including consideration of barriers to achieving this and resources that could make it easier.

Maximum number of participants: 45 – fully booked

15:30 – 16:45  Workshop  A 301 (Alzheimer hall)
Preclinical approaches to understanding nicotine addiction and developing novel smoking cessation treatments
Speakers: Philippe Faure; Mohammed Shoaib

This interactive preclinical workshop aims to provide an update on our current understanding of nicotine dependence. Two presentations will review the different preclinical models used to delineate neural mechanisms and behavioural factors that are known to contribute to nicotine dependence. Evidence based findings from studies will be presented that aim to identify new targets for treatment intervention. Use of these preclinical models is critical in exploring the neurobiological substrates of reinforcement and withdrawal, the genetic bases or even redefining the concept of addiction.

Maximum number of attendees: no maximum

19:00 – 23:00  Conference gala dinner
For more information see page 59
### Scientific programme | Saturday, 8 September 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 09:30</td>
<td>Keynote lecture P (Marc Willemsen)</td>
<td>Hörsaal (Lecture hall)</td>
</tr>
<tr>
<td></td>
<td>The enormous time lag between recognising the tobacco problem and effective national tobacco control policies: searching for explanations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: D. Kotz</td>
<td></td>
</tr>
<tr>
<td>09:30 – 10:45</td>
<td>Oral session E4</td>
<td>Hörsaal (Lecture hall)</td>
</tr>
<tr>
<td></td>
<td>Socioeconomic inequalities in smoking and quitting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: C. Meyer / V. Boland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Socioeconomic inequalities in quitting and starting smoking within a weak tobacco control environment: Lesson learned from a longitudinal study in Indonesia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Amalia / Barcelona, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>E-cigarette use in England 2014–2017 as a function of socioeconomic profile</td>
<td></td>
</tr>
<tr>
<td></td>
<td>L. Kock / London, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>L. Shahab; R. West; J. Brown</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Time trends in social inequalities in smoking prevalence and secondhand smoke exposure among adolescents in Germany: recent findings from the KIGGS study</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Kuntz / Berlin, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td>J. Hoebel; J. Zeiher; A. Starker; T. Lampert</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tobacco Smoking among Vocational Students in one Federal State of Germany: A Driving Force of Widenring Health Inequalities</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Meyer / Greifswald, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. Ulbricht; J. Freyer-Adam; M. Hanke; S. Haug; U. John</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Technology-based smoking cessation interventions for disadvantaged groups: A systematic review and meta-analysis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>V. Boland / Randwick, Australia</td>
<td></td>
</tr>
<tr>
<td>09:30 – 10:45</td>
<td>Oral session P4</td>
<td>A 201 (Library)</td>
</tr>
<tr>
<td></td>
<td>Aspects of policy implementation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: S. Haw</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Impact of a Scottish Ban on Tobacco Displays at Point-of-Sale on Young People's Smoking Susceptibility: Findings from the DISPLAY Study</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. Haw / Stirling, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Best; F. Haseen; D. Currie; G. Ozakinci; M. Wilson</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adult smoker's perceptions of cigarette packaging with audio warning messages: A focus group study</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. Mitchell / Stirling, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Moodie; L. Baud</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Factors associated with Scottish prison staff and prisoner views of prison smoking bans</td>
<td></td>
</tr>
<tr>
<td></td>
<td>H. Sweeting / Glasgow, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>E. Demou; G. Logan; S. Semple; A. Brown; K. Hunt</td>
<td></td>
</tr>
</tbody>
</table>

### Key:
- B = basic / pre-clinical science
- C = clinical
- E = epidemiology / public health
- P = policy

### Scientific programme | Saturday, 8 September 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:45 – 10:45</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>11:15 – 12:30</td>
<td>Symposium E3</td>
<td>Hörsaal (Lecture hall)</td>
</tr>
<tr>
<td></td>
<td>New findings on e-cigarettes 2017–2018</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: P. Hajek</td>
<td></td>
</tr>
<tr>
<td></td>
<td>New data on links between vaping and smoking in young people (as part of the symposium New Finding on e-cigarettes 2017–2018)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>L. Baud / Stirling, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>New data on effects of vaping on smoking prevalence</td>
<td></td>
</tr>
<tr>
<td></td>
<td>R. West / London, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
Symposium E3 continued

New data on effects of e-cigarettes on smoking cessation
P. Hajek / London, United Kingdom

New data on safety of e-cigarettes
K. Farsalinos / Lamia, Greece

11:15 – 12:30  Symposium B1  A 301 (Alzheimer hall)
Tobacco heating system thinking out of the box
Chair: T. Effertz

Analysis of selected carcinogens in the emissions of “Heat not Burn” tobacco products
N. Mallock / Berlin, Germany; L. Böss; R. Burk; M. Danziger; T. Welsch; H. Hahn; H.L. Trieu; J. Hahn; E. Pieper; F. Henkler-Stephani; C. Hutzler; A. Luch

Tobacco heating system worsen central hemodynamics
K.F. Franzen / Luebeck, Germany; S. Belkin; S. Marwitz; I. Tangemann; K. Mortensen; M. Reppel; D. Droemann

The combined market for nicotine in Germany – Interdependencies and developments of regular and electronic products from an economic perspective
T. Effertz / Hamburg, Germany

11:15 – 12:30  Symposium C3  A 322 (Meeting room)
Tobacco cessation for patients with tuberculosis or COPD
Chairs: M. Böckmann / D. Kotz

Developing a tobacco cessation intervention that can be scaled-up within National Tuberculosis (TB) Programmes in low and middle income countries
H. Elsey / Leeds, United Kingdom; S. Warsi

Health worker capacity building to support TB patients to quit tobacco: Findings from a mixed methods study in Bangladesh, Nepal and Pakistan
H. Elsey / Leeds, United Kingdom; S. Warsi

TB patients’ perception of tobacco and willingness to quit in Pakistan: Findings from the TB&Tobacco study
M. Noor / Islamabad, Pakistan; R. Zahid; A. Khan; M. Böckmann

Prevalence, views and experience of e-cigarette use by COPD patients in The Birmingham COPD Cohort
A. Farley / Birmingham, United Kingdom; M. Swallow; R. Jordan; A. Enocson; A. Dickens; D. Kotz; D. Fitzmaurice; P. Adab

12:30 – 13:30  Closing session & Farewell lunch  Hörsaal (Lecture hall)
Closing remarks and presentation of the poster awards
Invitation to the 19th Annual Conference in Oslo, Norway
**Poster session overview**

**Thursday, 6 September 2018**

14:00 – 15:00  
**Poster session 1**  
Gym  
En1 – Electronic inhalation products - I  
En2 – Electronic inhalation products - II  
Vul – Vulnerable groups

14:00 – 15:00  
**Poster session 2**  
Foyer gym  
Di1 – Disease and healthcare - I  
Pol – Tobacco control policy

14:00 – 15:00  
**Poster session 3**  
Glass hall  
Ce2 – Smoking cessation and reduction - II  
Pre – Pregnancy and newborns  
Yo2 – Young people - II

**Friday, 7 September 2018**

14:00 – 15:00  
**Poster session 4**  
Gym  
En3 – Electronic inhalation products - III  
En4 – Electronic inhalation products - IV  
Epi – Epidemiology

14:00 – 15:00  
**Poster session 5**  
Foyer gym  
Di2 – Disease and healthcare - II

14:00 – 15:00  
**Poster session 6**  
Glass hall  
Bas – Pre-clinical and basic science  
Ce1 – Smoking cessation and reduction - I  
Med – Pharmacotherapy  
Yo1 – Young people - I

---

**Poster plan**

Key:  
Bas = Pre-clinical, basic science;  
Ce = Smoking cessation, relapse, treatment, outcomes, predictors;  
Di = Disease, healthcare;  
En = ENDS;  
Epi = Epidemiology;  
Med = Medication, varenicline, bupropion, cytisine, NRT;  
Pol = Tobacco control, legislation, policy;  
Pre = Pregnancy, newborn;  
Vul = Vulnerable groups, low SES, minorities;  
Yo = Young people, adolescents
Poster sessions | Thursday, 6 September 2018

**Poster session 1**

**En1 – Electronic inhalation products - I**

**Chair:** L. Brose

1. **En1-1**
   Evaluation of cardiovascular disease risk in smokers after switching to electronic nicotine delivery systems
   
   **D. Rafael / Kiew, Ukraine:** O. Sribna; O. Kvasha

2. **En1-2**
   Role of a new generation electronic cigarette on smoking displacement in smokers with schizophrenia: a prospective 3-month feasibility study
   
   **P. Caponnetto / Catania, Italy:** J. DiPiazza; L. Baud; D. Robson; M. Maglia; G. Askin; J. Kim; P. Christos; R. Polosa

3. **En1-3**
   Methodological approaches for Laboratory Evaluation of Electronic Nicotine Delivery Systems: Safety Assessment as a Part of Regulatory Strategy
   
   **O. Malysheva / Kiew, Ukraine:** A. Podrushnia

4. **En1-4**
   Is susceptibility to e-cigarettes among youth associated with tobacco and other substance use behaviors one year later? Results from the PATH study
   
   **N.E. Nicksic / Richmond, United States:** A.J. Barnes

5. **En1-5**
   Perceptions of e-cigarettes, differences between daily and non-daily users
   
   **N. Mayorga / Houston, United States:** L. Garey; M. Zvolensky

6. **En1-6**
   E-cigarettes for smoking cessation within healthcare settings: patients' perceptions and research feasibility
   
   **R. Holliday / Newcastle upon Tyne, United Kingdom:** L. Baud; S. McDonald; F. Sniehotta; E. McColl; V. Ryan; P. Preshaw

7. **En1-7**
   The effects of e-cigarettes or NRT as adjuvant in a smoking cessation group intervention. Results of a field study monitored 12 months after the intervention
   
   **C. Kröger / Munich, Germany:** D. Piontek

8. **En1-8**
   E-cigarette Sensation and Liking as a Function of Flavor and Nicotine Content: Differences by Sex and Genetic Taste Phenotype
   
   **E. Mead / Farmington, CT, United States:** C. Oncken; V. Duffy; M. Litt

9. **En1-9**
   E-cigarette use in Germany from 2014 to 2018
   
   **K. Schaller / Heidelberg, Germany:** S. Kahnert; U. Mons

10. **En1-10**
    Associations between reasons for use and e-cigarette use: Cross-sectional evidence from a UK-based cohort
    
    **J. Khouja / Bristol, United Kingdom:** M. Munafó; A. Taylor

---

**En2 – Electronic inhalation products - II**

**Chair:** L. Shahab

1. **En2-1**
   Electronic Nicotine Delivery Systems Digital Marketing? A case study in Spain
   
   **J.M. Rey-Pino / Granada, Spain:** E. Vassiljeva; K. Gallopel-Morvan; C. Moodie

2. **En2-2**
   Norms Towards Smoking and e-cigarette Use and Association with Product Use: Findings from the 2017 International Tobacco Control Project (ITC) Youth Survey in England, Canada and the United States
   
   **K. East / London, United Kingdom:** S. Hitchman; A. McNeill; D. Hammond

3. **En2-3**
   Is it safe to vape whilst breastfeeding? Postpartum women's opinions on e-cigarettes, using online forum discussions: a qualitative analysis
   
   **E. Johnston / Nottingham, European Union:** S. Cooper; T. Coleman; K. Campbell; S. Orton; S. Lewis

4. **En2-4**
   Messages matter: The TPD nicotine addiction health warning versus an alternative relative risk message on smokers' willingness to use and purchase an electronic cigarette
   
   **L. Dawkins / London, United Kingdom:** S. Cox; R. Ahmed; D. Frings

5. **En2-5**
   Perceived harmfulness of e-cigarettes. Prevalence rates in the population and predictive effects
   
   **R. Kaán / Budapest, Hungary:** J. Vág; M. Pénzes; L. Abafalvi; B. Kispely; P. Hermann

6. **En2-6**
   Trends in electronic cigarette use in young people in Great Britain 2013-2018
   
   **B. Eastwood / London, United Kingdom:** M. Dockrell; H. Cheeseman; D. Arnott

7. **En2-7**
   E-cigarette User Population in Turkey: A Closer Look
   
   **G. Yararbas / Izmir, Turkey:** B. Akyel; Y. Erdogan; S. Kara

---

**Key:** **Bas** = Pre-clincal, basic science; **Ce** = Smoking cessation, reacation, treatment, outcomes, predictors; **Di** = Disease, healthcare; **Epi** = Epidemiology; **Med** = Medication, varenicline, bupropion, cytisine; **NRT** = Tobacco control, legislation, policy; **Pre** = Pregnancy, newborn; **Vul** = Vulnerable groups, low SES, minorities; **Yo** = Young people, adolescents
**Poster sessions** | Thursday, 6 September 2018

<table>
<thead>
<tr>
<th>Poster session 1 continued</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vul – Vulnerable groups</strong></td>
</tr>
<tr>
<td>Chair: M. Kuipers</td>
</tr>
</tbody>
</table>

**Vul-1**
Use of social media to reduce second hand smoke among disadvantaged families – a participatory m-health approach

T. Weinmann / Munich, Germany; K. Radon; F. Sukalla; J. Gerlich; S. Barth; D. Nowak; V. Karmowski

**Vul-2**
Health-Related Quality of Life (HRQoL) Among Homeless Smokers: Risk and Protective Factors of Latent Class Membership

L. Garey / Houston, United States; L. Reitzel; J. Neisler; D. Kendzor; M. Zvolensky; C. Neighbors; D. Hernandez; M. Businelle

**Vul-3**
Young Adult Sexual Minority and Heterosexual Women’s Exposure to Tobacco Product Advertisements in the United States: An Analysis of the Population Assessment of Tobacco and Health Study

A. Tan / Boston, United States; D. McDonald; S. Lee; A. Fallin-Bennett; A. Sanders-Jackson

**Vul-4**
A Mixed-Methods Analysis to Explore Young Adult Sexual Minority Women’s Perceptions of Advertising Images Utilizing Sexual Identity Cues: Implications For Designing Targeted Anti-tobacco Messaging

A. Tan / Boston, United States; S. Lee; D. McDonald; A. Fallin-Bennett; A. Sanders-Jackson

**Vul-5**
Disentangling the effects of education, income and social status on cigarette smoking

T.F. Vedey / Oslo, Norway

**Vul-6**
Comparing vapourised nicotine products to standard behavioural treatment for low-socioeconomic status smokers a randomised controlled trial: a study protocol

V. Boland / Randwick, Australia

**Vul-7**
Factors associated with past use of treatment and short and long-term abstinence among low-economic status smokers

V. Boland / Randwick, Australia

**Vul-8**
"I can't do this, I'm failing." Low-socioeconomic status smoker and ex-smokers barriers to cessation: a qualitative study

V. Boland / Randwick, Australia

---

**Poster sessions** | Thursday, 6 September 2018

<table>
<thead>
<tr>
<th><strong>Poster session 2</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Di1 – Disease and healthcare - I</strong></td>
</tr>
<tr>
<td>Chair: I. Berlin</td>
</tr>
</tbody>
</table>

**Di1-1**
Exploring mental health professionals’ practice in relation to smoke-free policy within a mental health trust: A qualitative study using the COM-B model of behaviour change

C. Smith / London, United Kingdom; A. McNeill; K. Lock; L. Shahab

**Di1-2**
Adapting a smartphone App to support smoking cessation for smokers with severe mental illness: Kick.it

S. Lawn / Adelaide, Australia; P. Klein; G. Tsourtos; J. Van Agteren

**Di1-3**
Marijuana and Prescription Pain Reliever Use Among Cigarette Smokers

J. Cataldo / San Francisco, United States; R. Goldberg

**Di1-4**
The impact of smoking cessation training on knowledge, attitude ad self-efficacy among healthcare providers

S.I. Hasan / Lembah Pantai, Malaysia; F. Mohd Hairi; A.S. Amer Nordin

**Di1-5**
Training GPs to implement brief stop-smoking advice (5A or ABC method) in German primary care: study protocol of a pragmatic, cluster randomised controlled trial (the ABC-II trial)

S. Kastaun / Düsseldorf, Germany; J. Hildebrandt / Düsseldorf, Germany; C. Funke; D. Lubisch; S. Becker; V. Leve; O. Reddemann; D. Kotz

**Di1-6**
Public acceptance for healthcare and tobacco control policies: results from the nationally representative German Study on Tobacco Use ("DEBRA")

S. Kastaun / Düsseldorf, Germany; D. Kotz; J. Brown; L. Shahab; M. Böckmann

**Di1-7**
Smoking related violence in mental health settings following the implementation of a smoke-free policy: A content analysis

G. Spaducci / London, United Kingdom; A. McNeill; K. Hubbard; D. Stewart; M. Yates; D. Robson

---

**Key:** Bas = Pre-clincal, basic science; Ce = Smoking cessation, recasualt, treatment, outcomes, predictors; Di = Disease, Healthcare; En = ENDS; Epi = Epidemiology; Med = Medication, varenicline, bupropion, cytisine, BOT; Pol = Tobacco control, legislation, policy; Pre = Pregnancy, newborn; Vul = Vulnerable groups, low SES, minorities; Yo = Young people, adolescents
Poster session 2 | Di continued

**Di1-8**
Patient views of a tobacco cessation intervention integrated into routine tuberculosis (TB) care in Bangladesh: findings from the TB&Tobacco process evaluation

M. Böckmann / Düsseldorf, Germany; E. Haowa Mustagfira; R. Huque; D. Kotz

**Di1-10**
Smoking, alcohol, depression and quality of life in Leber's hereditary optic neuropathy

A. Rabenstein / Munich, Germany; C. Catarino; T. Klopstock; T. Rüther

**Di1-11**
Do we need to consider the psychological profiles of smokers in a general hospital setting?

S. Van Lommel / Leuven, Belgium; K. Nackaerts; R. Bruffaerts

---

**Pol – Tobacco control policy**
Chair: A. McNeill

**Pol-1**
Changes in cigarette market and pricing during the implementation of plain packaging legislation in the United Kingdom

I. Bogdanovica / Nottingham, United Kingdom; M. Opazo Breton; J. Britton; Y. Huang

**Pol-2**
The effects of cigarette pack inserts with efficacy messages on responses to health warnings

O. Maynard / Bristol, United Kingdom; M. Munafò; M. Hall; S. Ferguson

**Pol-3**
Severity and susceptibility: measuring the perceived effectiveness and believability of tobacco health warnings

C. Sillero / Bristol, United Kingdom; O. Maynard; H. Gove; A. L. Skinner; M. Munafò

**Pol-4**
Building an Eastern European Network of Scholars for Tobacco Control: 2007 to present

K. Foley / Winston-Salem, United States; P. Balazs; Z. Ábrám; D. Easterling; M. Wolfson; J. Spangler; T. Rogers

**Pol-5**
Tobacco denormalization and smokers’ identities

M. Lund / Nydalen, Oslo, Norway; G. Sæbø

**Pol-6**
Approach to research and evaluation to inform tobacco product regulation

D. van Bemmel / Silver Spring, United States; C. Backinger

**Pol-7**
Adoption of legislation banning smoking in public places: Lessons learned from the Romanian experience

O. Blaga / Cluj-Napoca, Romania; G. Badescu

---

Poster sessions | Thursday, 6 September 2018

**Pol-8**
The Emergence of Dokha, an Alternative Tobacco Product, Through Social Media: Its Footprint and Impressions

A. Leinberger-Jabari / Abu Dhabi, United Arab Emirates; M. Memon; R. Ali; S. Sherman

**Pol-9**
Complete smokefree policies in mental health inpatient settings: Results from a mixed-methods evaluation before and after implementing national guidance

E. Ratschen / York, United Kingdom

---

**Ce2 – Smoking cessation and reduction - II**
Chair: A. Mathew

**Ce2-1**

C. Martinez-Vispo / Santiago de Compostela, Spain; E. Becoña; A. López-Durán; E. Fernández del Río; U. Martinez

**Ce2-2**
The Effect of Changes in the Abstinent State of Smokers on Task Performance and Craving

M. Grabski / London, United Kingdom; V. Curran; D. Nutt; S. Husbands; S. Ferguson; M. Munafò

**Ce2-3**
Tobacco and cannabis co-use: a systematic review and meta-analysis of treatment interventions

H. Walsh / London, United Kingdom; M. Duaso; A. McNeill

**Ce2-4**
Metacognitive Remediation Therapy: A Novel Cessation Program for Smokers with Psychosis

A. Ferketich / Columbus, United States; A. Moe; B. Keller-Hamilton; D. Weiss; J. Pine; N. Storey; A. Quisenberry; A. Zayas; K. Gilligan; N. Breitborde

**Ce2-5**
Time Varying Cravings and Depression Predicting Smoking Status Over the First Month of Treatment

S. Schiavon / Birmingham, United Kingdom; M. Sisson; K. Cropsey

**Ce2-6**
Preferences and needs of smokers and recent ex-smokers regarding stop smoking apps – a synthesis of findings from three interview studies

A. Herbec / London, United Kingdom; O. Perski; I. Tombor; J. Brown; L. Shahab; R. West

**Ce2-7**
Brief Intervention “Once and for all…I will stop smoking now” for public transportation drivers in Mexico City

G. Ponciano / CDMX, Mexico; A. Ruiz; L. Perez Cortes

---

Key: Bas = Pre-clincal, basic science; Ce = Smoking cessation, recusation, treatment, outcomes, predictors; Di = Disease, healthcare; En = ENDS; Epi = Epidemiology; Med = Medication, varenicline, bupropion, cytisine, NRT; Pol = Tobacco control, legislation, policy; Pre = Pregnancy, newborn; Vul = Vulnerable groups, low SES, minorities; Yo = Young people, adolescents
### Poster session 3 | Ce2 continued

#### Ce2-8
The cognitive-behavioural group programme "Smoke_less" for smoking reduction: results from a 2-year follow-up study  
M. Düerkop / Munich, Germany; A. Kiss; K. Eberhardt; C. Kröger; T. Rüther

#### Ce2-9
The cognitive-behavioural smoking reduction programme "Smoke_less": a prospective randomised study in outpatients  
T. Rüther / Munich, Germany; A. Kiss; K. Eberhardt; M. Düerkop; M. Miros; A. Rabenstein; C. Kröger; O. Pogarell

#### Ce2-10
Support And Intervention For Smoking Cessation And Relapse Prevention For Parents Of Babies Admitted To Neonatal Intensive Care  
A. Nichols / Norwich, United Kingdom; C. Notley / Norwich, United Kingdom; P. Clarke

### Prest - Pregnancy and newborns

**Chair:** M. Passey

#### Pre-1
Improving Health Providers' Smoking Cessation Knowledge, Attitudes and Practices with Pregnant Aboriginal Women  
Y. Bar-Zeev / Newcastle, Australia; M. Bovill; B. Boneskvi; M. Gruppetta; C. Oldmeadow; K. Palazzi; L. Atkins; J. Reath; G. Gould

#### Pre-2
Maternal tobacco and marijuana co-use: Impact on newborn neurobehavior  
G. Nolasco / Providence, United States; A. Corey; K. Borba; G. Papandonatos; M. McCallum; T. Kehoe; A. Salisbury; L. Stroud

#### Pre-3
Using behavioural economics to engage pregnant women in a smoking cessation trial – An online field experiment  
O. Blaga / Cluj-Napoca, Romania; C. Meghea; T.D. Frățilă

#### Pre-4
A mixed dissemination strategy for engagement of pregnant women in a smoking cessation Randomized Controlled Trial  
T.D. Frățilă / Cluj-Napoca, Romania; O. Blaga; C. Meghea

#### Pre-5
Use of e-cigarettes among Romanian smoker and ex-smoker pregnant women  
I. Bratulescu / Cluj-Napoca, Romania; O. Blaga; C. Meghea

#### Pre-6
Predictors of smoking during pregnancy in a sample of Romanian pregnant women  
M. Dascal / Cluj-Napoca, Romania; O. Blaga; C. Meghea

---

**Key:** Bas = Pre-clincal, basic science; Ce = Smoking cessation, recuassion, treatment, outcomes, predictors; Di = Disease, healthcare; En = ENDs; Epi = Epidemiology; Med = Medication, varenicline, bupropion, cytisine, NRT; Pol = Tobacco control, legislation, policy; Pre = Pregnancy, newborn; Vul = Vulnerable groups, low SES, minorities; Yo = Young people, adolescents
### Poster sessions | Thursday, 6 September 2018

#### Poster session 3 | Yo2 continued

<table>
<thead>
<tr>
<th>Yo2-6</th>
<th>Early predictors of daily cannabis use in young adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. Dugas / Montreal, Canada; M.-P. Sylvestre; E. Ewusi-Boisvert; M. Chaiton; A. Montreuil; J. O’Loughlin</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Yo2-7</th>
<th>Subjective numeracy and emotional reactions to health warning labels: Responses from United States adult smokers and susceptible youth</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. Klein / Columbus, United States: A. Quisenberry; B. Shoots-Reinhard; D. Romer; E. Peters</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Yo2-8</th>
<th>Waterpipe Tobacco Smoking among University Students in Three Eastern Mediterranean Countries: Patterns, Place, and Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>R. Salloum / Gainesville, United States: R. Nakkash</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Yo2-9</th>
<th>Marketing controls and the decline of youth smoking in the UK from 2002–2016: findings from the Youth Tobacco Policy Survey</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Ford / Stirling, United Kingdom; A.M. Mackintosh; C. Moodie; L. Bauld; G. Hastings</td>
<td></td>
</tr>
</tbody>
</table>

### Poster sessions | Friday, 7 September 2018

#### Poster session 4

<table>
<thead>
<tr>
<th>En3-1</th>
<th>Social and environmental correlates of traditional cigarette and electronic cigarette use in high school students</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. Hoetger / Richmond, United States: A. Rudy; C. Cobb</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>En3-2</th>
<th>Pilot Study: Study Designed to Consider Regulatory Focus Aligned with Message Framing to Effectively Communicate Risk of Using Electronic Cigarettes among Young Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>K. Calabro / Houston, United States: G. Khalil; M. Chen; A. Prokhorov; C.L. Perry</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>En3-3</th>
<th>A simplified method for trapping aerosol condensate from electronic vapourising devices for chemical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>B. de Falco / Dundee, United Kingdom: E. Stephens; A. Fiore</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>En3-4</th>
<th>Monitoring the transitioning from cigarette smoking to electronic cigarette use on cardiovascular outcomes, psychometric parameters and relapse rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Bailey / London, United Kingdom: E. Macauley; H. Goss; P. Durrant; E. Zhuikova; N. Goldsmith; T. Marczylo</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>En3-5</th>
<th>Fate of pyrazines in the flavored liquids of e-cigarettes</th>
</tr>
</thead>
<tbody>
<tr>
<td>R. El Hage / Beirut, Lebanon: A. El Hellani; R. Salman; S. Talih; A. Shihadeh; N. Saliba</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>En3-6</th>
<th>The catalytic role of the metallic coils of electronic cigarettes in aldehyde formation</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. Saliba / Beirut, Lebanon: A. El Hellani; E. Honein; R. Salman; J. Zeaier; A. Shihadeh</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>En3-7</th>
<th>Carbon monoxide and hydrocarbon gases identified from Sub-ohm e-cigarettes at moderate powers</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. El Hellani / Beirut, Lebanon: S. Al Moussawi; R. El Hage; S. Talih; R. Salman; N. Karaoghlanian; A. Shihadeh; N. Saliba</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>En3-8</th>
<th>Film boiling: predicting the onset of a high-aldehyde regime in e-cigarettes</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. Talih / Beirut, Lebanon: R. Salman; E. Karam; N. Karaoghlanian; A. Shihadeh</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>En3-9</th>
<th>Nicotine and carbonyls yields from JUUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>R. Salman / Beirut, Lebanon: S. Talih; R. El Hage; E. Karam; N. Karaoghlanian; A. El Hellani; N. Saliba; A. Shihadeh</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>En3-10</th>
<th>Predicting nicotine emissions across electronic cigarette generations</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. Talih / Beirut, Lebanon: R. Salman; R. El Hage; N. Karaoghlanian; A. El Hellani; N. Saliba; A. Shihadeh</td>
<td></td>
</tr>
</tbody>
</table>

---

**Key:** Basc = Pre-clincal, basic science; Ce = Smoking cessation, nicotine, treatment, outcomes, predictors; Di = Disease, healthcare; En = ENDs; Epi = Epidemiology; Med = Medication, varenicline, bupropion, cytochrome, NRT; Pol = Tobacco control, legislation, policy; Pre = Pregnancy, newborn; Vul = Vulnerable groups, low SES, minorities; Yo = Young people, adolescents
En4 – Electronic inhalation products - IV

Chair: T. Rüther

En4-1 Associations between social norms for e-cigarettes and smoking, intention to quit smoking and use of e-cigarettes: Findings from the International Tobacco Control (ITC) Project European Surveys
M. McDermott / London, United Kingdom; K. East; S. Hitchman; A. McNeill; Y. Tountas; N. Bécuwe; E. Fernandez; U. Mons; A. Trofor; W.A. Zatoński; G.T. Fong; C. Vardavas

En4-2 Particle size distributions of aerosols emitted from high-power “sub-Ohm” Electronic Cigarette devices
M. Baassiri / Beirut, Lebanon; N. Karaoghlanian; S. Talih; R. Salman; E. Karam; A. Shihadeh

En4-3 Are we witnessing a ‘disruptive moment’ in tobacco control? A historical view at harm reduction, the precautionary principle, and the rise of the e-cigarette
M. Zatoński / London, United Kingdom; A. Brandt

En4-4 Preliminary nicotine delivery and subjective effect profile of a “Pod Mod” electronic cigarette (JUUL) and a “Heat-Not-Burn” tobacco product (IQOS)
T. Eisenberg / Richmond, United States; S. Maloney; A. Breland; E. Soule

En4-5 Sources of awareness of JUUL-brand electronic cigarettes among US adults
A. Tan / Boston, United States; M. Moran; J. Chen; S. Soneji; K. Choi

En4-6 The Influence Of The e-cigarette On The Practice Of Smoking Cessation Specialist
M. Pappens / Brussels, Belgium; L. Deboiserie; S. Schol; H. Boudrez

En4-7 Reported patterns of vaping to support long term abstinence from smoking
S. Gentry / Norwich, United Kingdom; E. Ward; R. Holland; L. Dawkins; C. Notley

En4-8 Heat-not-burn tobacco use and its associated factors in Chinese adults: a population-based survey in Hong Kong, China
V. Wu / Hong Kong, Hong Kong; M.P. Wang; S.Y. Ho; Y.T. Cheung; T. Tabuchi; A. Kwong; V. Lai; T.H. Lam

En4-9 Transitions in cigarette smoking associated with use of the JUUL vaping device among 18,799 adults in the United States
F. Haseen / United Kingdom; C. Russell; N. McKeegan

Epi – Epidemiology

Chair: A. Ford

Epi-1 Prevalence and determinants of susceptibility to tobacco smoking among students in The Gambia
I. Jallow / Nottingham, United Kingdom; J. Britton; T. Langley

Epi-2 How long do we need to measure to understand typical second-hand smoke presence in a home?
R. Dobson / Stirling, United Kingdom; D. Marzial; S. Semple

Epi-3 Long-term Nondaily Cigarette Smoking in the U.S.: Using Census Data from the Tobacco Use Supplement – Current Population Survey (TUS-CPS)
C. Reyes-Guzman / Bethesda, United States; N. Freedman; M. Inoue-Choi

Epi-4 Light and nondaily cigarette smoking: a changing population of tobacco users
C. Reyes-Guzman / Bethesda, United States

Epi-5 Is it Race or Income that Accounts for Differences in Smoking Behaviours and Outcomes?
M. Sisson / Birmingham, United States; S. Schiavon; K. Cropsey

Epi-6 Differences in mortality attributable to tobacco with respect to cause of death, location, gender and type of exposure to tobacco (smoking, smokeless tobacco or secondhand smoke)
L. Ramström / Täby, Sweden

Epi-7 Parental cannabis use is associated with cannabis uptake and use in offspring
E. Dugas / Montreal, Canada; N. Hanusalk; E.K. O’Loughlin; J. Winickoff; A. Montreuil; R.J. Wellman; M.-P. Sylvestre; J. O’Loughlin

Epi-8 The 100-cigarette lifetime criterion: Time for a change?
E. Dugas / Montreal, Canada; M.-P. Sylvestre; R.J. Wellman; J. O’Loughlin

Epi-9 Preference for flavors in tobacco products among adult tobacco users
E. Klein / Columbus, United States; A. Hinton; S. Cooper; C. Simons; A. Quisenberry; M.E. Wewers

Epi-10 Widespread belief that organic and additive-free tobacco products are less harmful than regular tobacco products: Results from the 2017 US Health Interview National Trends Survey
J. Pearson / Reno, United States; M. Moran; J. Lewis; A. Villanti; C. Delnever

Key: Bas = Pre-clincal, basic science; Ce = Smoking cessation, recuction, treatment, outcomes, predictors; Di = Disease, healthcare; En = ENDs; Epi = Epidemiology; Med = Medication, varenicline, bupropion, cytisine, NRT, Pil = Tobacco control, legislation, policy; Pre = Pregnancy, newborn; Vul = Vulnerable groups, low SES, minorities; Yo = Young people, adolescents
### Poster sessions | Friday, 7 September 2018

<table>
<thead>
<tr>
<th>14:00 – 15:00</th>
<th><strong>Poster session 5</strong></th>
<th>Foyer gym</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>D12 – Disease and healthcare - II</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chair:</strong> A. Farley</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>D12-1</strong></td>
<td>Reasons for smoking among adults with serious mental illness: Seeing the bigger picture</td>
<td></td>
</tr>
<tr>
<td>B. Keller-Hamilton / Columbus, United States: A. Moe; N. Breitborde; A. Lee; A. Ferketich</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>D12-2</strong></td>
<td>Implementation of smoking cessation into tuberculosis care in high-risk countries: easy or hard?</td>
<td></td>
</tr>
<tr>
<td>E. Kraikova / Prague, Czech Republic: I. Nohavova; K. Zvolska; A. Pankova; on behalf of the TB&amp;Tobacco Consortium</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>D12-3</strong></td>
<td>The interdependence between smoking and psychological comorbidity in patients with chronic obstructive pulmonary disease (COPD): Empirical evidence from pulmonary inpatient rehabilitation</td>
<td></td>
</tr>
<tr>
<td>S. Mühlig / Chemnitz, Germany: K. Schultz; F. Loth; M. Schuler; M. Wittmann</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>D12-4</strong></td>
<td>&quot;astra plus&quot; Health Competence and Tobacco free Nursing. A Program for Nursing Education in Germany.</td>
<td></td>
</tr>
<tr>
<td>C. Rustler / Berlin, Germany: A. Bühler; M. Borse-Rohmann; D. Sautter; A. Reusch</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>D12-5</strong></td>
<td>Proven performance and shared good practice – German Network for Tobacco Free Health Care Services</td>
<td></td>
</tr>
<tr>
<td>C. Rustler / Berlin, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>D12-6</strong></td>
<td>Tobacco cessation in Lung Cancer Centers in Germany. How supportive is the Certification process for Tobacco Free Healthcare Services?</td>
<td></td>
</tr>
<tr>
<td>C. Rustler / Berlin, Germany: C. Graf; E. Weiß-Gerlach</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>D12-7</strong></td>
<td>A systematic review of qualitative research on nurses who smoke and their experiences of delivering smoking cessation to patients</td>
<td></td>
</tr>
<tr>
<td>S. Zhang; P. Dunham; M. Duaso / London, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>D12-8</strong></td>
<td>Health Visitors provision of smoking cessation support for postpartum women</td>
<td></td>
</tr>
<tr>
<td>P.-N. Julia; M.J. Duaso / London, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>D12-9</strong></td>
<td>Implementation of Tobacco Training within Mental Health Centers: Clinician and Staff Change in Tobacco Use Knowledge</td>
<td></td>
</tr>
<tr>
<td>L. Gary / Houston, United States: C. Neighbors; I. Martinez Leal; C. Lam; W.T. Wilson; B. Kybursz; T. Stacey; V. Correa-Fernandez; T. Williams; M. Zvolensky; L. Reitzel</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>D12-10</strong></td>
<td>The Burden of Smoking on Population Health and Productivity in Malaysia</td>
<td></td>
</tr>
<tr>
<td>Q.Y. Tan / Selangor, Malaysia: E. Zomer; A. Owen; D. Liew</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

### Poster sessions | Friday, 7 September 2018

<table>
<thead>
<tr>
<th>14:00 – 15:00</th>
<th><strong>Poster session 6</strong></th>
<th>Glass hall</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bas – Pre-clinical and basic science</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chair:</strong> L. Dawkins</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bas-1</strong></td>
<td>Smoking and the Clock</td>
<td></td>
</tr>
<tr>
<td>N. Ghotbi / Munich, Germany: A. Rabenstein; T. Rüther; T. Roenneberg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bas-2</strong></td>
<td>Degradation of nicotine in smokers: will a new potent enzymatic approach work where nicotine vaccines have failed?</td>
<td></td>
</tr>
<tr>
<td>B. van Engelen / Maastricht, Netherlands: O. van Schayck; M. Kalnik; T. Thisted</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bas-3</strong></td>
<td>Urine or blood: does it matter how you calculate the nicotine metabolism ratio?</td>
<td></td>
</tr>
<tr>
<td>S. Ferguson / Hobart, Australia: C.K. Narkowicz; G.A. Jacobson</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bas-4</strong></td>
<td>Changes to exposure, biochemical, brain dynamics and psychometric markers following the transition from cigarette smoking to vaping: The SmokeFreeBrain Study</td>
<td></td>
</tr>
<tr>
<td>T. Marczylo / Oxford, United Kingdom: E. Zhiukova; N. Goldsmith; E. Macauley; P. Durrant; H. Goss; L. Kovatsi; D. Fragou; L. Liu; A. Ioannides; A. Bailey</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bas-5</strong></td>
<td>Artificial sweetener content in flavored cigarillos</td>
<td></td>
</tr>
<tr>
<td>H.C. Erythropel / New Haven, United States: G. Kong; T.M. de Winter; S. O’Malley; S. Krishnan-Sarin; S.E. Jordt; P.T. Anastas; J.B. Zimmerman</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bas-6</strong></td>
<td>Corticostriatal glutamate circuits and their contribution to smoking relapse vulnerability</td>
<td></td>
</tr>
<tr>
<td>B. Froeliger / Charleston, United States: P. McConnell; J. Prisciandaro</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bas-7</strong></td>
<td>A Theoretical Model of Cognitive Control and Negative Affect as Interactive Contributors to Smoking Behavior</td>
<td></td>
</tr>
<tr>
<td>D. Evans / Tampa, United States</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bas-8</strong></td>
<td>Effect of smoking status on neuronal responses to graphic cigarette warning labels</td>
<td></td>
</tr>
<tr>
<td>Y. Schultz / Munich, Germany: T. Rüther; C. Wirth; A. Chrubok; A. Rabenstein; D. Keese; B. Ertl-Wagner; O. Pogarell; S. Karch</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Key:** Bas = Pre-clinical, basic science; Ce = Smoking cessation, reduction, treatment, outcomes, predictors; Di = Disease, healthcare; En = ENDS; Epi = Epidemiology; Med = Medication, varenicline, bupropion, cytisine, NRT; Pol = Tobacco control, legislation, policy; Pre = Pregnancy, newborn; Vul = Vulnerable groups, low SES, minorities; Yo = Young people, adolescents
Poster sessions | Friday, 7 September 2018

**Poster session 6 continued**

**Ce1 – Smoking cessation and reduction - I**

**Chair:** K. Cropsey

**Ce1-1**
The Effect of Positive and Negative Affect on Early Treatment Milestones in the Context of Integrated Smoking Treatment

*B. Kauffman / Houston, United States;* L. Garey; K. Manning; S. Taha; N. Schmidt; C. Neighbors; M. Zvolensky

**Ce1-2**
Understanding Quit Patterns: Subgroups, Predictors, and Long-Term Abstinence

*K. Manning / Houston, United States;* L. Garey; D. McCarthy; M. Gallagher; J. Shepherd; M. Orr; N. Schmidt; M. Zvolensky

**Ce1-3**
Does the duration of a smoking cessation programme have an effect on cessation rate? Comparing two group programs lasting one resp. three sessions

*C. Kröger / Munich, Germany;* R. Braun; J. Gröll

**Ce1-4**
Smoking cessation intention associated with advice to quit smoking by clinicians and laypersons

*S.-W. Park / Daegu, South Korea;* J.H. Hwang; H.G. Jung

**Ce1-5**
Effects of smoking and smoking cessation on work productivity and work ability: a longitudinal analysis

*S. Troelstra / Amsterdam, Netherlands;* C. Boot; J. Harting; G. Geuskens; A. Kunst; A. van der Beek

**Ce1-6**
Which withdrawal symptoms predict relapse in a structured group intervention for smoking cessation?

*S. Kuitunen-Paul / Dresden, Germany;* T. Müller; B. Röwer; M. Jakob; P.T. Kuitunen; C. Scheffel; M.N. Smolka; G. Bühringer

**Ce1-7**
Pain and Negative Affect following a Self-Guided Quit Attempt: An Ecological Momentary Assessment Study

*D. Cain / Seattle, United States;* C. Jacobs; N. Benowitz; N. Rigotti; M. Nides

**Ce1-8**
Cognitive Bias Modification as an add-on intervention for treatment-as-usual in tobacco dependence

*E. Reibert / Munich, Germany;* C. Wittekind; O. Pogarell; T. Ehring; T. Rüther

**Ce1-9**
Residential hospital treatment exclusively for smoking cessation – results of a pilot study

*J. Leifert / Freiburg, Germany;* U. Engler; B. Pschichholz; C. Schulz; A. Jaehne

---

**Med – Pharmacotherapy**

**Chair:** S. Tonstad

**Med-1**
Interest in using varenicline and its effects in people who both smoke and vape

*P. Hajek / London, United Kingdom;* S. Peerbux; K. Pittacio; C. Smith; D. Przuł

**Med-2**
Updated safety profile of cytisine for smoking cessation from recent studies

*P. Tutka / Rzeszów, Poland;* D. Vinnikov; N. Brimkulov; R.J. Courtney; N. Benowitz

**Med-3**
12-months abstinence in smokers with and without schizophrenia in clinical setting

*L. Stepankova / Prague, Czech Republic;* E. Kralikova; A. Pankova; K. Zvolska

**Med-4**
A comparison of the craving profile of a novel nicotine replacement therapy vs nicotine patch during the first two weeks of a quit attempt: A non-inferiority study

*S. Ferguson / Hobart, Australia;* R. Wood-Baker; T. Jahnel; P.H. Ruane; P. Otto; M. Morrell

**Med-5**
Does a smartphone app supporting use of nicotine replacement therapy improve short-term quit rates and adherence? Findings from a pragmatic pilot randomized controlled trial of NRT2Quit

*A. Herbec / London, United Kingdom;* J. Brown; L. Shahab; R. West; T. Raupach

**Med-6**
"If I’d known..." – a theory-informed systematic analysis of missed opportunities in optimising use of nicotine replacement therapy and accessing relevant support: A qualitative study

*A. Herbec / London, United Kingdom;* I. Tombor; L. Shahab; R. West

**Med-7**
The length of tobacco dependence pharmacotherapy: what to recommend?

*E. Kralikova / Prague, Czech Republic;* Z. Adamcekova; L. Stepankova; K. Zvolska; A. Pankova

**Med-8**
Are there variation in the distribution frequency of polymorphism favorable to varenicline or bupropion according to different ethnic groups?

*P. Gaya / São Paulo, Brazil;* J. Scholz; J.R.D. Santos; P.R.X. Tomaz; T.M.O. Abe; M. Nassif Junior; A.D.C. Pereira; P.C.D. Santos

**Med-9**
A multicenter, double-blind, randomized, placebo-controlled phase 2b trial of cytisine in adult smokers

*D. Cain / Seattle, United States;* C. Jacobs; N. Benowitz; N. Rigotti; M. Nides
## Poster sessions | Friday, 7 September 2018

### Poster session 6 continued

<table>
<thead>
<tr>
<th>Yo1 – Young people - I</th>
<th>Chair: C. Vardavas</th>
</tr>
</thead>
</table>

#### Yo1- 1
Smoking in the sample of Slovak adolescents – results from the Y.A.B.S. study  
**J. Babjakova / Bratislava, Slovakia;** J. Babjaková; D. Vondrova; L. Sevcikova; A. Filova; J. Jurkovicová; L. Argalasova; M. Weitzman

#### Yo1- 2
How to promote smoke-free homes among young parents in low-income areas?  
**E. van Wijk / Amsterdam, Netherlands;** R. Overberg; J. Harting

#### Yo1- 3
Tobacco Use and Associated Knowledge and Perceptions of Risks and Benefits Among International Students at United States Mid-Atlantic Universities  
**C. Hoetger / Richmond, United States;** A. Cariello; P. Perrin; A. Barnes; C. Cobb

#### Yo1- 4
Modification of television’s effects on adolescent cigarette use by attention disorders  
**B. Keller-Hamilton / Columbus, United States;** M. Roberts; M. Slater; A. Ferketich

#### Yo1- 5
Does “de-normalization” change? Trends in the de-normalization of smoking in German adolescents  
**M. Mlinarić / Halle (Saale), Germany;** S. Günther; I. Moor; K. Heilmann; L. Hoffmann; M. Richter

#### Yo1- 6
Factors associated with smoking cessation attempts in Korean adolescents  
**N.L. Park / Seoul, South Korea;** H.-J. Cho

#### Yo1- 7
Evaluation and Dissemination of ASPIRE (A Smoking Prevention Interactive Experience) Among Youth  
**A. Prokhorov / Houston, United States;** S. Marani; A. Arya; G. Montes; Y. Pyrtle; C. Fernandez; S. Johnson; K. Calabro

#### Yo1- 8
Sociodemographic Disparities in Tobacco Smoke Exposure Among U.S. Nonsmoking Adolescents  
**A.L. Merianos / Cincinnati, United States;** R.A. Jandarov; E.M. Mahabee-Gittens

#### Yo1- 9
Predictors of high programme exposure among adolescents participating in a smoking prevention intervention in Romania  
**V. Nădășan / Tîrgu Mureș, Romania;** K. Foley; M. Pénzes; L. Ferencz; Z. Ábrám; R. Urban

#### Yo1- 10
Correlations between nicotine beliefs and perceived susceptibility and severity of nicotine and tobacco products in U.S. young adults  
**A. Villanti / Burlington, United States;** S. Naud; J. West; J. Pearson; O. Wackowski; E. Hair; J. Rath; R. Niaura
**Social programme | Welcome reception**

**Thursday, 6 September 2018, 18:30 – 21:00**

Do not miss the chance to mingle and mix with researchers, friends and colleagues from all over Europe. Be our guest at the welcome reception with free drinks and delicious snacks and appetizers.

**Admission:** Included in the registration fee (advance booking required)

**Venue:** Bavarian State Parliament – Maximilianeum

Bayerischer Landtag

Max-Planck-Str. 1

81672 Munich

*Please use the reception at the east gate (Ostporte) for entrance.*

**Directions:** Take underground U4 (direction Arabellapark) or U5 (direction Neuperlach Süd), from Theresienwiese to Max-Weber-Platz. From there it is only a few more steps to the Maximilianeum. See map on page 18.

**Important Note:** Due to safety regulations, advance bookings are required. Please have your ID card with you for admission.

---

**Social programme | Conference gala dinner**

**Friday, 7 September 2018, 19:00 – 23:00**

The BMW Welt is one of the first buildings representing a new generation of communication buildings for the 21st century, where the corporation goes into dialogue with visitors from all over the world – a place to present the BMW Group brands – BMW, MINI and Rolls-Royce Motor Cars – as an impressive experience. This means: To see, feel, hear, smell, taste the brands – in brief: To experience the world of the brands of BMW Group with all senses.

Get enchanted that night at the Restaurant Bavarie where you can enjoy a Bavarian meal in the modern setting of the BMW exhibition. It is a place where sustainability and regionalism meets high-quality design and new automobile technologies.

Experience a wonderful night in a beautiful ambiance with a spectacular view from the terrace of the restaurant to the Olympic Park and the Olympic Centre and enjoy a special musical supporting programme.

**Admission:** 65.00 € (advance booking required)

**Venue:** Restaurant BAVARIE

Am Olympiapark 1

80809 Munich

**Directions:** Take U3 (underground), direction Olympia-Einkaufszentrum/Moosach, from Sendlinger Tor to Olympiazentrum. From there it is only a few more steps to the BMW Welt. See map on page 18.
### Exhibitors and supporters

We would like to take this opportunity to thank all sponsors, exhibitors and supporters.

#### Platinum sponsors

- Medscape Education Global
- Pfizer

#### Silver sponsor

- Johnson & Johnson
- nicorette

### Exhibitors

<table>
<thead>
<tr>
<th>No.</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Bundeszentrale für gesundheitliche Aufklärung</td>
</tr>
<tr>
<td>2</td>
<td>AKYmedical plus</td>
</tr>
<tr>
<td>3</td>
<td>Ashfield Healthcare GmbH im Auftrag von Johnson &amp; Johnson</td>
</tr>
<tr>
<td>4</td>
<td>Pfizer Pharma GmbH</td>
</tr>
<tr>
<td>5</td>
<td>Berlin Chemie AG</td>
</tr>
<tr>
<td>6</td>
<td>NichtraucherHelden.de – bytes2business GmbH</td>
</tr>
<tr>
<td>7</td>
<td>Generation Rauchfrei - Austrian Medical Students’ Association</td>
</tr>
<tr>
<td>8</td>
<td>rauchfrei plus – Deutsches Netz Rauchfreier Krankenhäuser &amp; Gesundheitseinrichtungen</td>
</tr>
</tbody>
</table>

![Map – first floor](image)

- **Catering**: Yellow
- **Lecture hall**: Purple

---

_Society for Research on Nicotine and Tobacco (SRNT) Europe_  
18th Annual Conference in Munich, Germany, 6–8 September 2018
Author index

A
Aaronwitz, C. 27
Abafalvi, L. 41
Abe, T.M.O. 55
Aboour, N. 47
Abram, Z. 44, 56
Adab, P. 36
Adamcekova, Z. 55
Adams, C. 31
Agteren, J. Van 43
Ahmed, R. 41
Akbar, S. 32
Akely, B. 41
Albery, I. 35
Ali, R. 45
Amalia, B. 34
Amer Nordin, A.S. 43
amos, A. 24, 30
Anastas, P.T. 35, 53
Anderson, E.L. 35
Angus, K. 27
Anker, T. 47
Argalasova, L. 56
Arnott, D. 41
Arya, A. 56
Aschenbrenner, A. 41
Askin, G. 40
Assi, R. 23
Atkins, L. 46
Atuegwu, N. 25
Atzendorf, J. 41
Augusburger, A. 43
B
Baassiri, M. 50
Babjaková, J. 56
Backinger, C. 30, 44
Badescu, G. 44
Bahde, A. 30
Bailey, A. 49, 53
Balazs, P. 44
Ba, O. 28
Barnes, A. 56
Barnes, A.L. 40
Barth, S. 42
Bar-Zeev, Y. 25, 29, 46
Bauld, L. 25, 29, 31, 34, 35, 40, 48
Becker, S. 43
Becoña, E. 29, 45
Bécuwe, N. 50
Beek, A. van der 54
Belkin, S. 36
Bennett, C. 30, 44
Benowitz, N. 55
Berger, D. 29
Berlin, I. 25, 32, 43, 47
Best, C. 24, 27, 30, 34
Bickhardt, J. 23
Bischof, G. 26
Blaga, O. 44, 46, 47
 Bölckmann, M. 36, 43, 44
Bodenmann, P. 43
Bogdanovic, I. 44
Böhme, F. 27, 30
Boland, V. 34, 42
Bommelé, J. 47
Bonevski, B. 25, 29, 46
Bonse-Rohmann, M. 52
Boot, C. 54
Booth, P. 35
Borba, K. 46
Böss, L. 36
Botello, G. 26, 47
Boudrez, H. 50
Bovill, M. 46
Brandt, A. 50
Bratulescu, I. 46
Braun, R. 54
Breitborde, N. 45, 52
Brelend, A. 50
Breslin, E. 24
Breton, M. Opazo 44
Brewer, J. 27
Brimkulov, N. 55
Britton, J. 44, 51
Brod, A. 26
Brose, L. 24, 25, 29, 40
Brown, A. 24, 31, 34
Brown, J. 34, 43, 45, 55
Brown, T. 25
Bruffaerts, R. 44
Bucevski, M. 47
Buchaner, L. 24, 35
Bue, A.-F. 47

Author index

B
Bühl, A. 52
Bühringer, G. 30, 54
Burk, R. 36
Burris, J. 31
Businelle, M. 42

C
Cain, D. 55
Calabro, K. 26, 47, 49, 56
Calder, R. 25
Camarà, B. 28
Campbell, K. 41
Caponnetto, P. 40
Cariello, A. 56
Carmona, M. 28
Cataldo, J. 43
Catarino, C. 44
Chao, M. 48
Cheeseman, H. 41
Chen, J. 50
Chen, M. 49
Cheeralie, M. 27
Cheung, Y.T. 50
Cho, H.-J. 56
Choi, K. 50
Christos, P. 40
Chrobok, A. 53
Clair, C. 23, 32, 43
Clare, R. 47
Clancy, L. 24
Clarke, P. 46
Clément, L. 23
Cobb, C. 49, 56
Cola, M. 23
Coleman, T. 41, 47
Conradt, B. 23
Cooper, S. 41, 51
Corcoran, O. 29
Corey, A. 46
Correa-Fernandez, V. 52
Cortes, L. Perez 45
Courtney, R.J. 55
Couto, M.-L. Do 23
Cox, S. 33, 41, 43
Critchlow, N. 27
Cropsey, K. 29, 30, 32, 45, 51, 54
Curran, V. 45

D
Dallery, J. 27
Danziger, M. 36
Dascal, M. 46
Davey Smith, G. 35
Dawkins, L. 29, 41, 43, 50, 53
Deboise, L. 50
de Falco, B. 49
Delaney, H. 24
Delle, S. 41
Delineo, C. 51
Demou, S. 34
Derrick, J. 54
de Winter, T.M. 35, 53
Dickens, A. 36
Diouf, F. 28
DiPiazza, J. 40
Ditre, J. 54
Dyjoadhiningrat-Hol, K. 47
Dobson, R. 51
Dockrell, M. 41
Dornelas, E. 47
Droemman, D. 36
Duaso, M. 45, 52
Duaso, M.J. 52
 Dü尔kop, M. 46
Duffy, V. 40
Dugas, E. 29, 48, 51
Duhme, K. 25, 26
Dunham, P. 52
Durrant, P. 49, 53

E
eadie, D. 27
Easterling, D. 44
East, K. 41, 50
Eastwood, B. 41
Eberhardt, K. 46
Effertz, T. 36
Ehrring, T. 54
Eissenberg, T. 50
El-Khoury, F. 28
Elsey, H. 36
Engler, U. 54
Enocson, A. 36
Author index

Erdogan, Y. 41
Ertl-Wagner, B. 53
Erythropel, H.C. 35, 53
Evans, D. 53
Ewusi-Boisvert, E. 48

F
Fairchild, V. 27
Falkai, P. 23
Fallin-Bennett, A. 42
Fanous, N. 47
Farley, A. 36, 52
Farsalinos, K. 36
Faure, P. 33
Federico, B. 24
Feronczi, L. 56
Ferguson, S. 44, 45, 53, 55
Ferketic, A. 45, 52, 56
Fernandez, C. 56
Fernandez, E. 50
Fernández del Río, E. 29, 45
Flore, A. 49
Fitzmaurice, D. 36
Foley, K. 44, 56
Fong, G.T. 50
Ford, A. 48, 51
Fragou, D. 53
Franzen, K.F. 36
Frätiă, T.D. 46
Freedman, N. 51
Freyer-Adam, J. 34
Fring, D. 35, 41
Froeliger, B. 53
Funke, C. 43

G
Gage, S. 32
Gallagher, M. 54
Gallopel-Morvan, K. 30, 41, 47
Garey, L. 40, 42, 52, 54
Garrison, K. 27
Gaya, P. 55
Gencer, B. 23
Gentry, S. 50
Gerlich, J. 42
Geuskens, G. 54
Ghosh, K. 35
Ghotbi, N. 53
Gilligan, K. 45
Girvalaki, C. 29
Goecke, M. 25, 26
Goldberg, R. 43
Goldsmith, N. 49, 53
Gomes de Matos, E. 41
Goniewicz, M.L. 25
Goss, H. 49, 53
Gould, G. 25, 29, 46
Gove, H. 44
Grabski, M. 45
Grah, C. 52
Grattan, K. 23
Gravier, B. 43
Gröll, J. 54
Großkopf, C. 27
Grupetta, M. 25, 29, 46
Gueorguieva, R. 27
Günther, S. 56
Guzman, M. 31

H
Hage, R. 35, 49
Hahn, H. 36
Hahn, J. 36
Hair, E. 56
Hajek, P. 35, 36, 55
Hall, M. 44
Hammerton, G. 35
Hammond, D. 41
Hanewinkel, R. 26
Hanke, M. 34
Hanusaik, N. 29, 51
Haowa Mustagfira, E. 44
Hardeman, W. 25
Hartling, J. 54, 56
Hasan, K.M. 30
Hasan, S.I. 43
Haseen, F. 24, 27, 34, 50
Hastings, G. 48
Haug, S. 26, 34
Haw, S. 27, 30, 34
Heilmann, K. 56
Heindl, T. 23
Hellani, A. 49
Henklar-Stephani, F. 36

Herbee, A. 45, 55
Hermann, P. 41
Hernandez, D. 42
Herrmann, E. 32
Hewer, R. 24, 30
Hildebrandt, J. 43
Hill, S. 24, 30
Hilton, S. 47
Hinton, A. 51
Hitchman, S. 27, 41, 50
Hitsman, B. 31
Hoebel, J. 34
Hoek, J. 30, 47
Hoetger, C. 49, 56
Hoffmann, L. 24, 35, 56
Holland, R. 25, 50
Holliday, R. 40
Holloway, A. 32
Holmes, L. 26
Honein, E. 49
Hostina, A. 47
Ho, S.Y. 50
Hourani, M. 35
Huang, Y. 44
Hubbard, K. 43
Hummel, K. 30
Hunt, K. 24, 34
Hushands, S. 45
Hutzler, C. 36
Hwang, J.H. 47, 54

I
Inoue-Choi, M. 51
Ioannides, A. 53
Isensee, B. 26

Jaquier, V. 43
Jardim, C. 54
Johnson, S. 56
Johnston, E. 41
Johnston, J. 31
John, U. 26, 34
Jordan, R. 36
Jordt, S.E. 35
Jordt, S.E. 35, 53
Julia, P.N. 52
Jung, H.G. 54

K
Kaan, R. 41
Kahnert, S. 40
Kalhan, R. 31
Kalnik, M. 53
Kaprio, J. 27
Karam, E. 35, 49, 50
Karaoghlanian, N. 35, 49, 50
Kara, S. 41
Karch, S. 53
Karnowskii, V. 42
Kassianos, A. 31
Kastaus, S. 24, 29, 43
Kauffmann, B. 54
Keeler, D. 53
Kehoe, T. 46
Keller-Hamilton, B. 45, 52, 56
Kendzor, D. 42
Keogan, S. 24
Khalil, G. 47, 49
Khan, A. 36
Khouja, J. 40
Kimber, C. 29
Kim, J. 40
Kinnunen, J.M. 24
Kispélyi, B. 41
Kiss, A. 46
Klein, E. 48, 51
Klein, P. 43
Klingenberg, R. 23
Klopotock, T. 44
Kock, L. 34, 43
Kohler, E. 35
Kong, G. 53
Korhonen, T. 27
<table>
<thead>
<tr>
<th>Author index</th>
<th>Author index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kotz, D.</td>
<td>McColl, E.</td>
</tr>
<tr>
<td>23, 24, 29, 34, 36, 43, 44</td>
<td>40</td>
</tr>
<tr>
<td>Kovatsi, L.</td>
<td>McConnell, P.</td>
</tr>
<tr>
<td>53</td>
<td>53</td>
</tr>
<tr>
<td>Kralkikova, E.</td>
<td>McDermott, M.</td>
</tr>
<tr>
<td>52, 55</td>
<td>50</td>
</tr>
<tr>
<td>Kranzler, H.</td>
<td>McDonald, D.</td>
</tr>
<tr>
<td>47</td>
<td>42</td>
</tr>
<tr>
<td>Kraus, L.</td>
<td>McDonald, S.</td>
</tr>
<tr>
<td>41</td>
<td>40</td>
</tr>
<tr>
<td>Krishnan-Sarin, S.</td>
<td>McKeeganey, N.</td>
</tr>
<tr>
<td>27, 53</td>
<td>50</td>
</tr>
<tr>
<td>Kroemer, N.B.</td>
<td>McNeill, A.</td>
</tr>
<tr>
<td>27, 30</td>
<td>24, 25, 27, 31, 41, 43, 44, 45, 50</td>
</tr>
<tr>
<td>Kröger, C.</td>
<td>McRobbie, H.</td>
</tr>
<tr>
<td>25, 26, 40, 41, 46, 54</td>
<td>29</td>
</tr>
<tr>
<td>Kuipers, L.Y.</td>
<td>Mead, E.</td>
</tr>
<tr>
<td>30</td>
<td>25, 40, 47</td>
</tr>
<tr>
<td>Kuipers, M.</td>
<td>Meade, C.</td>
</tr>
<tr>
<td>24, 27, 30, 42</td>
<td>32</td>
</tr>
<tr>
<td>Kuitunen-Paul, S.</td>
<td>Meghea, C.</td>
</tr>
<tr>
<td>30, 54</td>
<td>46, 47</td>
</tr>
<tr>
<td>Kuitunen, P.T.</td>
<td>Melchior, M.</td>
</tr>
<tr>
<td>, 30, 54</td>
<td>28</td>
</tr>
<tr>
<td>Kunst, A.</td>
<td>Memon, M.</td>
</tr>
<tr>
<td>24, 30, 54</td>
<td>45</td>
</tr>
<tr>
<td>Kunz, B.</td>
<td>Mendizabal, M.</td>
</tr>
<tr>
<td>34</td>
<td>35</td>
</tr>
<tr>
<td>Kuo, C.-L.</td>
<td>Merianis, A.L.</td>
</tr>
<tr>
<td>47</td>
<td>47, 56</td>
</tr>
<tr>
<td>Kurtti, A.</td>
<td>Meyer, C.</td>
</tr>
<tr>
<td>31</td>
<td>26, 34</td>
</tr>
<tr>
<td>Kvetsha, O.</td>
<td>Miros, M.</td>
</tr>
<tr>
<td>40</td>
<td>46</td>
</tr>
<tr>
<td>Kwong, A.</td>
<td>Mitchell, D.</td>
</tr>
<tr>
<td>50</td>
<td>34</td>
</tr>
<tr>
<td>Kyburz, B.</td>
<td>Mitchell, F.</td>
</tr>
<tr>
<td>52</td>
<td>31</td>
</tr>
<tr>
<td>Kyriakos, C.</td>
<td>Milanić, M.</td>
</tr>
<tr>
<td>31</td>
<td>24, 35, 56</td>
</tr>
<tr>
<td></td>
<td>Moe, A.</td>
</tr>
<tr>
<td></td>
<td>45, 52</td>
</tr>
<tr>
<td></td>
<td>Mohd Hairi, F.</td>
</tr>
<tr>
<td></td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>Mons, U.</td>
</tr>
<tr>
<td></td>
<td>26, 30, 31, 40, 50</td>
</tr>
<tr>
<td></td>
<td>Montes, G.</td>
</tr>
<tr>
<td></td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Montgomery, D.</td>
</tr>
<tr>
<td></td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>Montreuil, A.</td>
</tr>
<tr>
<td></td>
<td>48, 51</td>
</tr>
<tr>
<td></td>
<td>Moodie, C.</td>
</tr>
<tr>
<td></td>
<td>27, 29, 30, 34, 41, 48</td>
</tr>
<tr>
<td></td>
<td>Moor, l.</td>
</tr>
<tr>
<td></td>
<td>24, 56</td>
</tr>
<tr>
<td></td>
<td>Moran, M.</td>
</tr>
<tr>
<td></td>
<td>50, 51</td>
</tr>
<tr>
<td></td>
<td>Morgenstern, M.</td>
</tr>
<tr>
<td></td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>Morrell, M.</td>
</tr>
<tr>
<td></td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>Morris, J.</td>
</tr>
<tr>
<td></td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Mortensen, E.</td>
</tr>
<tr>
<td></td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Mortensen, K.</td>
</tr>
<tr>
<td></td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Moussawi, S.</td>
</tr>
<tr>
<td></td>
<td>Al 49</td>
</tr>
<tr>
<td></td>
<td>Muggli, M.</td>
</tr>
<tr>
<td></td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>Mühlig, S.</td>
</tr>
<tr>
<td></td>
<td>23, 52</td>
</tr>
<tr>
<td></td>
<td>Mullen, K.-A.</td>
</tr>
<tr>
<td></td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Muller, O.</td>
</tr>
<tr>
<td></td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Müller, T.</td>
</tr>
<tr>
<td></td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>Munafó, M.</td>
</tr>
<tr>
<td></td>
<td>27, 29, 33, 35, 40, 44, 45</td>
</tr>
<tr>
<td></td>
<td>Nakaerts, K.</td>
</tr>
<tr>
<td></td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>Nādājan, V.</td>
</tr>
<tr>
<td></td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Nakkash, R.</td>
</tr>
<tr>
<td></td>
<td>48</td>
</tr>
<tr>
<td></td>
<td>Nanchen, D.</td>
</tr>
<tr>
<td></td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Narkowicz, C.K.</td>
</tr>
<tr>
<td></td>
<td>53</td>
</tr>
<tr>
<td></td>
<td>Nassif Junior, M.</td>
</tr>
<tr>
<td></td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>Naud, S.</td>
</tr>
<tr>
<td></td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Naughton, F.</td>
</tr>
<tr>
<td></td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Neighbors, C.</td>
</tr>
<tr>
<td></td>
<td>42, 52, 54</td>
</tr>
<tr>
<td></td>
<td>Neisler, J.</td>
</tr>
<tr>
<td></td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>Néri, C.</td>
</tr>
<tr>
<td></td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>Nauria, R.</td>
</tr>
<tr>
<td></td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Nichols, A.</td>
</tr>
<tr>
<td></td>
<td>46</td>
</tr>
<tr>
<td></td>
<td>Nickson, F.</td>
</tr>
<tr>
<td></td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Nides, M.</td>
</tr>
<tr>
<td></td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>Noble, S.</td>
</tr>
<tr>
<td></td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Nohavova, I.</td>
</tr>
<tr>
<td></td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>Nolasco, G.</td>
</tr>
<tr>
<td></td>
<td>46</td>
</tr>
<tr>
<td></td>
<td>Noor, M.</td>
</tr>
<tr>
<td></td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Nostikasari, D.</td>
</tr>
<tr>
<td></td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>Notley, C.</td>
</tr>
<tr>
<td></td>
<td>25, 31, 46, 49, 50</td>
</tr>
<tr>
<td></td>
<td>Nowak, D.</td>
</tr>
<tr>
<td></td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>Nutt, D.</td>
</tr>
<tr>
<td></td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>Nyuys, P.</td>
</tr>
<tr>
<td></td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>O</td>
</tr>
<tr>
<td></td>
<td>Oldmeadow, C.</td>
</tr>
<tr>
<td></td>
<td>29, 46</td>
</tr>
<tr>
<td></td>
<td>O’Loughlin, E.K.</td>
</tr>
<tr>
<td></td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>O’Loughlin, J.</td>
</tr>
<tr>
<td></td>
<td>29, 48, 51</td>
</tr>
<tr>
<td></td>
<td>O’Malley, S.</td>
</tr>
<tr>
<td></td>
<td>27, 53</td>
</tr>
<tr>
<td></td>
<td>Oncken, C.</td>
</tr>
<tr>
<td></td>
<td>25, 40, 47</td>
</tr>
<tr>
<td></td>
<td>Orr, M.</td>
</tr>
<tr>
<td></td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>Orth, B.</td>
</tr>
<tr>
<td></td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Orton, S.</td>
</tr>
<tr>
<td></td>
<td>25, 41</td>
</tr>
<tr>
<td></td>
<td>Oto, P.</td>
</tr>
<tr>
<td></td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>Overberg, R.</td>
</tr>
<tr>
<td></td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Owen, A.</td>
</tr>
<tr>
<td></td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>Ozakinci, G.</td>
</tr>
<tr>
<td></td>
<td>24, 27, 34</td>
</tr>
<tr>
<td></td>
<td>P</td>
</tr>
<tr>
<td></td>
<td>Pacek, L.</td>
</tr>
<tr>
<td></td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>Palazzi, K.</td>
</tr>
<tr>
<td></td>
<td>29, 46</td>
</tr>
<tr>
<td></td>
<td>Pal, P.</td>
</tr>
<tr>
<td></td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>Palviainen, T.</td>
</tr>
<tr>
<td></td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>Pankova, A.</td>
</tr>
<tr>
<td></td>
<td>52, 55</td>
</tr>
<tr>
<td></td>
<td>Papadakis, S.</td>
</tr>
<tr>
<td></td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>Papandonatos, G.</td>
</tr>
<tr>
<td></td>
<td>46</td>
</tr>
<tr>
<td></td>
<td>Pappens, M.</td>
</tr>
<tr>
<td></td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>Park, N.L.</td>
</tr>
<tr>
<td></td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Park, S.-W.</td>
</tr>
<tr>
<td></td>
<td>47, 54</td>
</tr>
<tr>
<td></td>
<td>Passey, M.</td>
</tr>
<tr>
<td></td>
<td>31, 46</td>
</tr>
</tbody>
</table>
Author index

Paulus, D. 54
Payton, J. 31
Pbert, L. 29
Pearce, J. 27
Pearson, J. 51, 56
Peerbux, S. 55
Pénzes, M. 41, 56
Pereira, A.D.C. 55
Perelman, J. 24
Perez, M. 25
Pergadia, M.L. 27
Perneeczky, R. 23
Perrin, P. 56
Perry, C. 40
Perry, C.L. 47, 54
Perry, C. 45
Perrin, P. 56
23
Perneczky, R. 49
Perez, M. 27
Pereira, A.D.C. 55
Peerbux, S. 56
Pearson, J. 56
27
Pearce, J. 54
Pbert, L. 29
Payton, J. 54
Paulus, D. 54

Author index

Sanders-Jackson, A. 42
Sankey, H. 47
Santos, J.R.D. 55
Santos, P.C.D. 55
Sautter, D. 52
Schaller, K. 40
Schayck, O. van 53
Scheffel, C. 30, 54
Scheffels, J. 30
Scheinin, D. 27
Schiafoni, S. 30, 45, 51
Schmidt, N. 54
Schol, S. 50
Scholtz, L. 23
Schol, J. 55
Schreuders, M. 24
Schuler, J. 52
Schulz, K. 52
Schulz, Y. 53
Schulz, C. 54
Sebrie, E. 27, 28
Semple, S. 34, 51
Senra, C. 29
Shahab, L. 24, 25, 34, 41, 43, 45, 55
Shepherd, J. 54
Sherman, S. 45
Shi, Z. 27
Shoaib, M. 33
Shoots-Reinhard, B. 48
Silliker, C. 44
Simms, J. 31
Simonavicius, E. 24
Simons, C. 51
Sinclair, L. 26
Sinclair, L. 54
Sniehotta, F. 40
Sobol, J. 41
Sobol, E. 50
So, V.H.T. 30
Spaducci, G. 43
Spangler, J. 44
Spear, S. 31
Springvloet, L. 47
Squegilia, L. 32
Sribnà, O. 40
Stacey, T. 52
Stark, A. 34
Stead, M. 21
Stephankova, L. 55
Stephens, E. 49
Stewart, D. 43
Storey, N. 45
Stroud, L. 46
Subash, P. 31
Sukalla, F. 42
Swallow, M. 36
Sweeting, H. 24, 36
Sweitzer, M. 32
Sylvestre, M.-P. 29, 48, 51

Tabuchi, T. 50
Taha, S. 54
Talih, S. 35, 49, 50
Tan, A. 42, 50
Tan, Q.Y. 52
Tangemann, I. 36
Tappin, D. 31
Taylor, A. 35, 40
Thisted, T. 53
Thrul, J. 26
Thurlow, S. 47
Timpson, N.J. 35
Tomaz, P. 55
Tombo, I. 45, 55
Tomiko, R. 32
Tonstad, S. 55
Tountas, Y. 50
Trieu, H.L. 36
Troestra, S. 54
Trofor, A. 50
Tsourtsos, G. 43
Tutka, P. 55
Twyman, L. 29

Q
Quisenberry, A. 45, 48, 51

R
Rabenstein, A. 44, 46, 53
Rabon, K. 42
Rafael, D. 40
Ramström, L. 51
Rath, J. 56
Ratschen, E. 45
Raupach, T. 55
Reath, J. 46
Reddemann, O. 43
Reibert, E. 54
Reid, R.D. 23
Reitzel, L. 42, 52
Relton, C.L. 35
Reppel, M. 36
Reusch, A. 52
Reyes-Guzman, C. 51
Rey Miguel, J. 47
Rey-Pino, J.M. 41
Richmond, R.C. 35
Richter, M. 24, 35, 56
Digotti, N. 55
Rimpelä, A. 24
Roberts, M. 56
Robson, D. 25, 40, 43
Rodondi, N. 23
Rodríguez-Cano, R. 29
Roenneberg, T. 53
Rogers, T. 44
Rojiani, R. 27
Rolfe, M. 31
Romer, D. 48
Rüwer, B. 54
Ruane, P.H. 55
Rudy, A. 49
Ruz, A. 45
Rumpf, H.J. 26
Russell, C. 50
Russell, S. 26, 47
Rustler, C. 52
Rüther, T. 23, 26, 44, 46, 50, 53, 54
Ryan, V. 40

S
Sæbø, G. 44
Sagna, M. 28
Salazar, C. 32
Saliba, N. 35, 49
Salisbury, A. 46
Saloum, R. 48
Salman, R. 35, 49, 50
Author index

U
Ulbricht, S. 26, 34
Urban, R. 56
Ussher, M. 25

V
Vág, J. 41
van Engelen, B. 53
van Laar, M. 47
van Lommel, S. 44
Vardavas, C. 29, 30, 31, 50, 56
Vassiljeva, E. 41
Vedey, T.F. 42
Vidrine, D. 26, 47
Villanti, A. 25, 51, 56
Vinnikov, D. 55

W
Wackowski, O. 56
Walsh, H. 45
Walter, K. 28
Wang, A.-L. 27
Wang, M.P. 50
Ward, E. 31, 50
Warsi, S. 36
Weinmann, T. 42
Weishaar, H. 47
Weiss, D. 45
Weiß-Gerlach, E. 52
Weitzman, M. 56
Wellman, R.J. 51
Welsch, T. 36
West, J. 56
West, R. 33, 34, 35, 45, 55
Wewers, M.E. 51
Wijk, E. van 56
Willemsen, M. 24, 34
Williams, T. 52
Wilson, M. 24, 27, 34
Wilson, W.T. 52
Windecker, S. 23
Winickoff, J. 29, 51
Wirth, C. 53
Wittekind, C. 54
Wittmann, M. 52

Wolfson, M. 44
Wood-Baker, R. 55
Wootton, R. 27
Wu, Y. 50

Y
Yararbas, G. 41
Yates, M. 43
Yount, S. 31

Z
Zahid, R. 36
Zahnd, T. 43
Zatoński, M. 30, 50
Zatoński, W.A. 50
Zayas, A. 45
Zeaiter, J. 49
Zeier, J. 34
Zhang, S. 52
Zhuikova, E. 49, 53
Zimmerman, J.B. 35, 53
Zomer, E. 52
Zvolensky, M. 40, 42, 52, 54
Zvoliska, K. 52, 55

Notes
Satellitensymposium mit freundlicher Unterstützung der Pfizer Pharma GmbH

Medikamentös unterstützte Rauchentwöhnung im Spannungsfeld zwischen Gesetzgebung und Evidenz.
Sonntag, den 9. September 2018
10:30 – 12:00 Uhr

Vorsitz: Dr. Alexander Rupp, Stuttgart

Agenda

10:30 Uhr  Einführung und Begrüßung

10:40 Uhr  Rauchentwöhnung in Deutschland: Status quo und internationaler Vergleich
Dr. Thomas Hering, Berlin

11:00 Uhr  Die Relevanz einer konsequenten Rauchentwöhnung bei Patienten mit kardiovaskulären Vorerkrankungen
Prof. Dr. Joachim Weil, Lübeck

11:20 Uhr  Die ATEM-Studie: Ergebnisse eines Pilotprojektes zur Vollfinanzierung der Tabakentwöhnung durch die GKV
Prof. Dr. Stephan Mühlig, Chemnitz

11:40 Uhr  Diskussion und Austausch

12:00 Uhr  Zusammenfassung und Ende der Veranstaltung

Klinikum der Ludwig-Maximilians-Universität München, Klinik für Psychiatrie und Psychotherapie Nußbaumstraße 7, 80336 München